Date,Articles
2007-01-30,"{""abstract"": ""The supply of low-cost generic versions of cancer and AIDS treatments for the developing world could be blocked if Novartis wins a legal challenge to India\u2019s patent law."", ""web_url"": ""https://www.nytimes.com/2007/01/30/business/worldbusiness/30novartis.html"", ""snippet"": ""The supply of low-cost generic versions of cancer and AIDS treatments for the developing world could be blocked if Novartis wins a legal challenge to India\u2019s patent law."", ""lead_paragraph"": "" NEW DELHI, Jan. 29 \u0097 The supply of low-cost generic versions of cancer and AIDS treatments for the developing world could be blocked if Novartis wins a legal challenge to India\u2019s patent law, patients\u2019 rights groups have contended. "", ""print_section"": ""C"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Battle Pits Patent Rights Against Low-Cost Generic Drugs"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Battle Pits Patent Rights Against Low-Cost Generic Drugs"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""glocations"", ""value"": ""India"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic and Brand Name Products"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2007-01-30T05:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""World Business"", ""byline"": {""original"": ""By Amelia Gentleman"", ""person"": [{""firstname"": ""Amelia"", ""middlename"": null, ""lastname"": ""Gentleman"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/a104750c-bdb5-5ec5-9bd5-f3264b0aea1b"", ""word_count"": 580, ""uri"": ""nyt://article/a104750c-bdb5-5ec5-9bd5-f3264b0aea1b""}"
2007-03-19,"{""abstract"": ""Bristol-Myers Squibb has inspired all kinds of takeover speculation recently. There has been less talk about Wyeth, an even larger pharmaceuticals giant that Catherine Arnold, an analyst at Credit Suisse, thinks could be an acquisition target as well. In a report Monday on possible mergers and acquisitions activity in the drug industry, Ms. Arnold also identified two drugmakers that appear to be \u201cnatural acquirers\u201d: GlaxoSmithKline and Novartis. "", ""web_url"": ""https://dealbook.nytimes.com/2007/03/19/diagnosing-the-next-big-drug-deal/"", ""snippet"": """", ""lead_paragraph"": ""Bristol-Myers Squibb has inspired all kinds of takeover speculation recently. There has been less talk about Wyeth, an even larger pharmaceuticals giant that Catherine Arnold, an analyst at Credit Suisse, thinks could be an acquisition target as well. In a report Monday on possible mergers and acquisitions activity in the drug industry, Ms. Arnold also identified two drugmakers that appear to be \u201cnatural acquirers\u201d: GlaxoSmithKline and Novartis. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Diagnosing the Next Big Drug Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2007-03-19T18:08:04+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By"", ""person"": [], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/f6f2da75-653f-5059-b906-2da2fc9e4f99"", ""word_count"": 294, ""uri"": ""nyt://article/f6f2da75-653f-5059-b906-2da2fc9e4f99""}"
2007-04-04,"{""abstract"": ""MicroChips has secured $13.4 million in a round of funding led by the Novartis Venture Fund, the venture capital arm of Swiss drug giant Novartis. Other investors include CSK Venture Capital of Japan, Polaris Venture Partners, IDG Ventures, Medtronic, Boston Scientific, and the Boston University Community Technology Fund. "", ""web_url"": ""https://dealbook.nytimes.com/2007/04/04/novartis-leads-134-million-round-for-microchips/"", ""snippet"": """", ""lead_paragraph"": ""MicroChips has secured $13.4 million in a round of funding led by the Novartis Venture Fund, the venture capital arm of Swiss drug giant Novartis. Other investors include CSK Venture Capital of Japan, Polaris Venture Partners, IDG Ventures, Medtronic, Boston Scientific, and the Boston University Community Technology Fund. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis Leads $13.4 Million Round for MicroChips"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2007-04-04T11:34:49+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d403bcc1-cb4a-57a6-81c9-d202eb41d0a0"", ""word_count"": 101, ""uri"": ""nyt://article/d403bcc1-cb4a-57a6-81c9-d202eb41d0a0""}"
2007-04-12,"[{""abstract"": ""Nestl\u00e9 is expected to announce that it is buying the baby food giant currently owned by Novartis, a Swiss-based company."", ""web_url"": ""https://www.nytimes.com/2007/04/12/business/12gerber.html"", ""snippet"": ""Nestl\u00e9 is expected to announce that it is buying the baby food giant currently owned by Novartis, a Swiss-based company."", ""lead_paragraph"": "" Nestl\u00e9, the world\u2019s largest food company, is expected to announce today that it is buying the baby food giant Gerber for an estimated $5 billion, people involved in the transaction said yesterday."", ""print_section"": ""C"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Deal Expected From Nestl\u00e9 to Buy Gerber for $5 Billion"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Deal Expected From Nestl\u00e9 To Buy Gerber For $5 Billion"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""NOVARTIS"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Nestle SA"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2007-04-12T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Martin and Andrew Ross Sorkin"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Martin"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Andrew"", ""middlename"": ""Ross"", ""lastname"": ""Sorkin"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/37f15e79-2603-5b70-a820-bb94414764d9"", ""word_count"": 405, ""uri"": ""nyt://article/37f15e79-2603-5b70-a820-bb94414764d9""}, {""abstract"": ""Nestl\u00e9 is expected to announce that it is buying the baby food giant, which is currently own by Novartis, a Swiss-based company."", ""web_url"": ""https://www.nytimes.com/2007/04/12/business/12gerber-web.html"", ""snippet"": ""Nestl\u00e9 is expected to announce that it is buying the baby food giant, which is currently own by Novartis, a Swiss-based company."", ""lead_paragraph"": "" Nestl\u00e9, the world\u2019s largest food company, is expected to announce today that it is buying the baby food giant Gerber, for an estimated $5 billion, people involved in the transaction said yesterday."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Nestl\u00e9 Expected to Buy Gerber in $5 Billion Deal"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2007-04-12T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Martin and Andrew Ross Sorkin"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Martin"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Andrew"", ""middlename"": ""Ross"", ""lastname"": ""Sorkin"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d35ee44a-541a-593d-90b4-b4cfb8a2194d"", ""word_count"": 404, ""uri"": ""nyt://article/d35ee44a-541a-593d-90b4-b4cfb8a2194d""}, {""abstract"": "" Nestl\u00e9, the world\u2019s largest food company, agreed to buy the baby food giant Gerber for $5.5 billion in cash to extend its push into the health and wellness category. Gerber, famous for its Gerber Baby ads, is currently owned by Novartis, the Swiss pharmaceuticals company, which has been selling noncore businesses in recent years to focus on health care. Separately, Novartis said Thursday it had named Joseph Jimenez, previously of the Blackstone Group, the private equity firm, to be chief executive of its consumer health division. "", ""web_url"": ""https://dealbook.nytimes.com/2007/04/12/nestle-to-buy-gerber-for-55-billion/"", ""snippet"": """", ""lead_paragraph"": "" Nestl\u00e9, the world\u2019s largest food company, agreed to buy the baby food giant Gerber for $5.5 billion in cash to extend its push into the health and wellness category. Gerber, famous for its Gerber Baby ads, is currently owned by Novartis, the Swiss pharmaceuticals company, which has been selling noncore businesses in recent years to focus on health care. Separately, Novartis said Thursday it had named Joseph Jimenez, previously of the Blackstone Group, the private equity firm, to be chief executive of its consumer health division. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Nestl\u00e9 to Buy Gerber for $5.5 Billion"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2007-04-12T11:05:53+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d45754be-51d5-5f95-80b7-bcee74dd55c2"", ""word_count"": 291, ""uri"": ""nyt://article/d45754be-51d5-5f95-80b7-bcee74dd55c2""}]"
2007-04-13,"{""abstract"": ""The deal fits with Nestl\u00e9\u2019s focus on wellness and Novartis\u2019s strategy of selling its noncore businesses."", ""web_url"": ""https://www.nytimes.com/2007/04/13/business/worldbusiness/13gerber-web.html"", ""snippet"": ""The deal fits with Nestl\u00e9\u2019s focus on wellness and Novartis\u2019s strategy of selling its noncore businesses."", ""lead_paragraph"": "" Nestl\u00e9, the world\u2019s largest food company, said today that it had agreed to buy Gerber, the baby food company, for $5.5 billion."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Nestl\u00e9 Agrees to Buy Gerber From Novartis"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""</hl1> <hl2 class="", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""NOVARTIS"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Nestle SA"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2007-04-13T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""World Business"", ""byline"": {""original"": ""By Andrew Martin and Andrew Ross Sorkin"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Martin"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Andrew"", ""middlename"": ""Ross"", ""lastname"": ""Sorkin"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/60f97ff1-ea4e-50b6-80b6-a9d1470fc734"", ""word_count"": 445, ""uri"": ""nyt://article/60f97ff1-ea4e-50b6-80b6-a9d1470fc734""}"
2007-05-14,"{""abstract"": ""Mylan Laboratories has agreed to buy the generic drug unit of Merck, the German drug maker, for 4.9 billion euros ($6.7 billion) in cash. The acquisition will make Mylan the world\u2019s third-largest maker of copycat versions of drugs, after Teva Pharmaceuticals of Israel and Novartis of Switzerland."", ""web_url"": ""https://dealbook.nytimes.com/2007/05/14/mylan-labs-in-deal-to-buy-german-generic-drug-unit/"", ""snippet"": """", ""lead_paragraph"": ""Mylan Laboratories has agreed to buy the generic drug unit of Merck, the German drug maker, for 4.9 billion euros ($6.7 billion) in cash. The acquisition will make Mylan the world\u2019s third-largest maker of copycat versions of drugs, after Teva Pharmaceuticals of Israel and Novartis of Switzerland."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Mylan Labs in Deal to Buy German Generic Drug Unit"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2007-05-14T12:00:41+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c79e226d-c5a7-5f57-b251-c9fe6a13a8cc"", ""word_count"": 114, ""uri"": ""nyt://article/c79e226d-c5a7-5f57-b251-c9fe6a13a8cc""}"
2007-06-23,"{""abstract"": ""David E. I. Pyott, president and chief executive of Allergan, discussed the company\u2019s recent developments."", ""web_url"": ""https://www.nytimes.com/2007/06/23/business/23interview.html"", ""snippet"": ""David E. I. Pyott, president and chief executive of Allergan, discussed the company\u2019s recent developments."", ""lead_paragraph"": ""David E. I. Pyott, 53, became president and chief executive of Allergan in 1998 after spending his earlier management career in the nutrition subsidiaries of Novartis and Sandoz. The stock stood at $15.74 and the company was best known for its contact lens care solutions."", ""print_section"": ""C"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/06/23/business/23interview.75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2007/06/23/business/23interview.75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Making Botox Both Medicine and Cosmetic"", ""kicker"": ""Saturday Interview"", ""content_kicker"": null, ""print_headline"": ""Making Botox Both Medicine And Cosmetic"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Eyes and Eyesight"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Botox (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Plastic Surgery"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INCORPORATED"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-06-23T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Barnaby J. Feder"", ""person"": [{""firstname"": ""Barnaby"", ""middlename"": ""J."", ""lastname"": ""Feder"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""Interview"", ""_id"": ""nyt://article/90d3264f-9bc7-5096-9d45-90efd7afe778"", ""word_count"": 743, ""uri"": ""nyt://article/90d3264f-9bc7-5096-9d45-90efd7afe778""}"
2007-07-06,"{""abstract"": ""Pfizer settled a lawsuit against a rival drug maker, Novartis, for alleged infringement of a United States patent for the antibiotic medicine Zithromax. Pfizer sued Novartis and Sandoz, a unit operating in the United States, in February 2006 in federal court in Wilmington, Del., saying it would be irreparably harmed by the rival companies\u2019 use of the invention for forms of crystal azithromycin; Pfizer sought unspecified damages. The parties have agreed to settle all claims over the 2005 drug patent, and the suit was dismissed June 25, according to court papers. Pfizer is based in New York, and Novartis is based in Basel, Switzerland."", ""web_url"": ""https://www.nytimes.com/2007/07/06/business/worldbusiness/06fobriefs-DRUGSUITSETT_BRF.html"", ""snippet"": ""Pfizer settled a lawsuit against a rival drug maker, Novartis, for alleged infringement of a United States patent for the antibiotic medicine Zithromax. Pfizer sued Novartis and Sandoz, a unit operating in the United States, in February 2006 in fe..."", ""lead_paragraph"": ""Pfizer settled a lawsuit against a rival drug maker, Novartis, for alleged infringement of a United States patent for the antibiotic medicine Zithromax. Pfizer sued Novartis and Sandoz, a unit operating in the United States, in February 2006 in federal court in Wilmington, Del., saying it would be irreparably harmed by the rival companies\u2019 use of the invention for forms of crystal azithromycin; Pfizer sought unspecified damages. The parties have agreed to settle all claims over the 2005 drug patent, and the suit was dismissed June 25, according to court papers. Pfizer is based in New York, and Novartis is based in Basel, Switzerland."", ""print_section"": ""C"", ""print_page"": ""6"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Switzerland: Drug Suit Settled"", ""kicker"": ""World Business Briefing"", ""content_kicker"": null, ""print_headline"": ""Switzerland: Drug Suit Settled"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""NOVARTIS"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Switzerland"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-07-06T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""World Business"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""Brief"", ""_id"": ""nyt://article/1b816873-7671-5534-8939-b62d4786ce5f"", ""word_count"": 108, ""uri"": ""nyt://article/1b816873-7671-5534-8939-b62d4786ce5f""}"
2007-07-16,"{""abstract"": ""COMPANY REPORTS Earnings season gets into full swing, particularly for technology, financial and drug companies. Reports will come from Charles Schwab and Mattel (Monday); Coca-Cola, I.B.M., Intel, Johnson & Johnson, Merrill Lynch, Novartis, Wells Fargo and Yahoo (Tuesday); Abbott Laboratories, Altria, AMR, Delta Air Lines, eBay, JPMorgan Chase, Pfizer, Southwest Airlines and United Technologies (Wednesday); Advanced Micro Devices, Bank of America, Bank of New York Mellon, Continental Airlines, Dow Jones, First Data, Google, Honeywell, Microsoft, Motorola and Wyeth (Thursday); and Boston Scientific, Caterpillar and Citigroup (Friday)."", ""web_url"": ""https://www.nytimes.com/2007/07/16/business/16ahead.html"", ""snippet"": ""COMPANY REPORTS Earnings season gets into full swing, particularly for technology, financial and drug companies. Reports will come from Charles Schwab and Mattel (Monday); Coca-Cola, I.B.M., Intel, Johnson & Johnson, Merrill Lynch, Novartis, Wells..."", ""lead_paragraph"": ""COMPANY REPORTS Earnings season gets into full swing, particularly for technology, financial and drug companies. Reports will come from Charles Schwab and Mattel (Monday); Coca-Cola, I.B.M., Intel, Johnson & Johnson, Merrill Lynch, Novartis, Wells Fargo and Yahoo (Tuesday); Abbott Laboratories, Altria, AMR, Delta Air Lines, eBay, JPMorgan Chase, Pfizer, Southwest Airlines and United Technologies (Wednesday); Advanced Micro Devices, Bank of America, Bank of New York Mellon, Continental Airlines, Dow Jones, First Data, Google, Honeywell, Microsoft, Motorola and Wyeth (Thursday); and Boston Scientific, Caterpillar and Citigroup (Friday)."", ""print_section"": ""C"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Looking Ahead"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Looking Ahead"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""International Business Machines Corp"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""United States Politics and Government"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Intel Corp"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""AIRLINES AND AIRPLANES"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Computers and the Internet"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2007-07-16T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": """", ""person"": [], ""organization"": null}, ""type_of_material"": ""Schedule"", ""_id"": ""nyt://article/0c6441f0-3edd-5f25-a4c5-05cc77f53064"", ""word_count"": 287, ""uri"": ""nyt://article/0c6441f0-3edd-5f25-a4c5-05cc77f53064""}"
2007-07-17,"{""abstract"": ""Novartis on Tuesday showed growing interest in pursuing takeovers, just as its core pharmaceuticals business suffered the most severe competition to date from lower-priced generic rival products."", ""web_url"": ""https://dealbook.nytimes.com/2007/07/17/novartis-may-seek-more-deals-to-boost-growth/"", ""snippet"": """", ""lead_paragraph"": ""Novartis on Tuesday showed growing interest in pursuing takeovers, just as its core pharmaceuticals business suffered the most severe competition to date from lower-priced generic rival products."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis May Seek More Deals to Boost Growth"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2007-07-17T11:14:53+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/371f3546-1e22-557e-aead-8ab3ae13a582"", ""word_count"": 82, ""uri"": ""nyt://article/371f3546-1e22-557e-aead-8ab3ae13a582""}"
2007-07-19,"{""abstract"": ""Ablation Frontiers, which develops treatments for cardiac arrhythmia, said it closed a $21.8 million round of venture funding led by Novartis Venture Fund. The round also included new investors Affinity Capital Management, Hexagon Investments and Trellis Health Ventures. "", ""web_url"": ""https://dealbook.nytimes.com/2007/07/19/ablation-frontiers-raises-218-million/"", ""snippet"": """", ""lead_paragraph"": ""Ablation Frontiers, which develops treatments for cardiac arrhythmia, said it closed a $21.8 million round of venture funding led by Novartis Venture Fund. The round also included new investors Affinity Capital Management, Hexagon Investments and Trellis Health Ventures. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Ablation Frontiers Raises $21.8 Million"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2007-07-19T11:00:45+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By"", ""person"": [], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1ca292e4-293f-5edb-8631-36ef354ea883"", ""word_count"": 84, ""uri"": ""nyt://article/1ca292e4-293f-5edb-8631-36ef354ea883""}"
2007-08-02,"[{""abstract"": ""Female drug sales workers claim the company discriminated against them in pay, promotions and personnel evaluations."", ""web_url"": ""https://www.nytimes.com/2007/08/02/business/01cnd-suit.html"", ""snippet"": ""Female drug sales workers claim the company discriminated against them in pay, promotions and personnel evaluations."", ""lead_paragraph"": ""A federal judge has ruled that female drug sales workers for Novartis Pharmaceuticals may proceed with a class-action gender discrimination lawsuit against the company."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Judge Allows Class-Action Bias Suit Against Novartis "", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""NOVARTIS"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2007-08-02T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Stephanie Saul"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/49ab9b32-6989-5693-8ab8-16730f9e5073"", ""word_count"": 496, ""uri"": ""nyt://article/49ab9b32-6989-5693-8ab8-16730f9e5073""}, {""abstract"": ""The suit, brought on behalf of female drug sales workers at Novartis, claims the company discriminated against them in pay, promotions and personnel evaluations."", ""web_url"": ""https://www.nytimes.com/2007/08/02/business/02suit.html"", ""snippet"": ""The suit, brought on behalf of female drug sales workers at Novartis, claims the company discriminated against them in pay, promotions and personnel evaluations."", ""lead_paragraph"": ""A federal judge has ruled that female drug sales workers for Novartis Pharmaceuticals may proceed with a class-action gender discrimination lawsuit against the company."", ""print_section"": ""C"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis Faces Class Action Over Sex Bias"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Novartis Faces Class Action Over Sex Bias"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""NOVARTIS"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Discrimination"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Women"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-08-02T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Stephanie Saul"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Saul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/6444c4c8-f5f1-5b1e-ab81-1d17b6f70fa8"", ""word_count"": 496, ""uri"": ""nyt://article/6444c4c8-f5f1-5b1e-ab81-1d17b6f70fa8""}]"
2007-08-07,"{""abstract"": ""Drug companies can continue to make less expensive generic drugs, many of which flow to the developing world, after an Indian court Monday rejected a patent law challenge."", ""web_url"": ""https://www.nytimes.com/2007/08/07/business/worldbusiness/07drug.html"", ""snippet"": ""Drug companies can continue to make less expensive generic drugs, many of which flow to the developing world, after an Indian court Monday rejected a patent law challenge."", ""lead_paragraph"": ""NEW DELHI, Aug. 6 \u2014 Indian companies will be free to continue making less expensive generic drugs, much of which flow to the developing world, after a court rejected a challenge to the patent law on Monday."", ""print_section"": ""C"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/08/07/business/07drug-600.jpg"", ""height"": 300, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2007/08/07/business/07drug-600.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 300}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2007/08/07/business/07drug-75.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2007/08/07/business/07drug-75.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Setback for Novartis in India Over Drug Patent"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Setback for Novartis in India Over Drug Patent Protection"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2007-08-07T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""World Business"", ""byline"": {""original"": ""By Amelia Gentleman"", ""person"": [{""firstname"": ""Amelia"", ""middlename"": null, ""lastname"": ""Gentleman"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/0cbc2403-880c-5ade-a211-eb5949a31494"", ""word_count"": 928, ""uri"": ""nyt://article/0cbc2403-880c-5ade-a211-eb5949a31494""}"
2007-09-01,"{""abstract"": ""Novartis has become the first company to win approval for a copy of Johnson & Johnson\u2019s Eprex anemia treatment, allowing it to offer cheaper versions to Europeans."", ""web_url"": ""https://www.nytimes.com/2007/09/01/business/01anemia.html"", ""snippet"": ""Novartis has become the first company to win approval for a copy of Johnson & Johnson\u2019s Eprex anemia treatment, allowing it to offer cheaper versions to Europeans."", ""lead_paragraph"": ""Novartis has become the first company to win approval for a copy of Johnson & Johnson\u2019s Eprex anemia treatment, allowing it to offer cheaper versions to Europeans."", ""print_section"": ""C"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Generic Anemia Drug Allowed"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Generic Anemia Drug Allowed"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2007-09-01T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e126befd-9c5a-5ea7-a9b9-d1704a9d2d3c"", ""word_count"": 241, ""uri"": ""nyt://article/e126befd-9c5a-5ea7-a9b9-d1704a9d2d3c""}"
2007-09-08,"{""abstract"": ""Daniel L. Vasella, chief executive of Novartis, discusses the challenges facing the health care system."", ""web_url"": ""https://www.nytimes.com/2007/09/08/business/08interview.html"", ""snippet"": ""Daniel L. Vasella, chief executive of Novartis, discusses the challenges facing the health care system."", ""lead_paragraph"": ""Daniel L. Vasella, chief executive of Novartis, the $39 billion pharmaceutical giant based in Switzerland, says that even though Americans have made progress in curing some diseases, they face a major increase in obesity- and aging-related diseases. Mr. Vasella recently discussed these challenges and criticized the Food and Drug Administration in the United States for failing to act more quickly to approve new drugs. "", ""print_section"": ""C"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""A Drug Maker\u2019s Views of What Ails Health Care"", ""kicker"": ""Saturday Interview"", ""content_kicker"": null, ""print_headline"": ""A Drug Maker\u2019s Views of What Ails Health Care"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""NOVARTIS"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Health Insurance and Managed Care"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2007-09-08T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By WILLIAM HOLSTEIN"", ""person"": [{""firstname"": ""William"", ""middlename"": null, ""lastname"": ""HOLSTEIN"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""Interview"", ""_id"": ""nyt://article/6a372234-993c-5af6-9f20-027c3d65dd4d"", ""word_count"": 985, ""uri"": ""nyt://article/6a372234-993c-5af6-9f20-027c3d65dd4d""}"
2007-10-01,"{""abstract"": ""The drug giant Novartis said that it would give its Cambridge, Mass., neighbor, the Massachusetts Institute of Technology, $65 million over 10 years to create a research program, likely to be the biggest in the world aimed at revolutionizing the way drugs are made."", ""web_url"": ""https://dealbook.nytimes.com/2007/10/01/novartis-gives-mit-65-million-for-drug-development/"", ""snippet"": """", ""lead_paragraph"": ""The drug giant Novartis said that it would give its Cambridge, Mass., neighbor, the Massachusetts Institute of Technology, $65 million over 10 years to create a research program, likely to be the biggest in the world aimed at revolutionizing the way drugs are made."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis Gives M.I.T. $65 Million for Drug Development"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2007-10-01T11:33:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/906025bc-28f3-5a22-8f7d-2f61e7aa7349"", ""word_count"": 253, ""uri"": ""nyt://article/906025bc-28f3-5a22-8f7d-2f61e7aa7349""}"
2008-04-07,"{""abstract"": ""Novartis has agreed to buy Nestle\u2018s majority stake in Alcon, the United States-based eye care business, in a deal worth up to $39 billion."", ""web_url"": ""https://dealbook.nytimes.com/2008/04/07/novartis-signs-39-billion-deal-for-nestles-alcon-stake/"", ""snippet"": """", ""lead_paragraph"": ""Novartis has agreed to buy Nestle\u2018s majority stake in Alcon, the United States-based eye care business, in a deal worth up to $39 billion."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Nestle in $39 Billion Deal to Sell Alcon"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2008-04-07T11:02:50+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/965d7f07-9899-51c2-8391-0255d5ee65bd"", ""word_count"": 588, ""uri"": ""nyt://article/965d7f07-9899-51c2-8391-0255d5ee65bd""}"
2008-04-08,"[{""abstract"": ""The Swiss drug maker Novartis said on Monday that it would pay Nestl\u00e9 $11 billion for a 25 percent stake in Alcon, the world\u2019s biggest eye care company."", ""web_url"": ""https://www.nytimes.com/2008/04/08/business/08eye.html"", ""snippet"": ""The Swiss drug maker Novartis said on Monday that it would pay Nestl\u00e9 $11 billion for a 25 percent stake in Alcon, the world\u2019s biggest eye care company."", ""lead_paragraph"": ""PARIS \u0097 The Swiss drug maker Novartis said on Monday that it would pay Nestl\u00e9 $11 billion for a 25 percent stake in Alcon, the world\u2019s biggest eye care company, in the first step of a deal that could become a full acquisition."", ""print_section"": ""C"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis and Nestl\u00e9 in a Deal for Alcon"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Novartis And Nestl\u00e9 In a Deal For Alcon"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Eyes and Eyesight"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""NOVARTIS"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Nestle SA"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Alcon Incorporated"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2008-04-08T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Jolly"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Jolly"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/6b719721-eb69-5355-a506-ed0e00132d26"", ""word_count"": 463, ""uri"": ""nyt://article/6b719721-eb69-5355-a506-ed0e00132d26""}, {""abstract"": ""The Swiss drug maker said that it would pay Nestl\u00e9 $11 billion for a 25 percent stake in Alcon, the world\u2019s biggest eye-care company."", ""web_url"": ""https://www.nytimes.com/2008/04/08/business/07cnd-Novartis.html"", ""snippet"": ""The Swiss drug maker said that it would pay Nestl\u00e9 $11 billion for a 25 percent stake in Alcon, the world\u2019s biggest eye-care company."", ""lead_paragraph"": ""PARIS \u0097 The Swiss drug maker Novartis said on Monday that it would pay Nestl\u00e9 $11 billion for a 25 percent stake in Alcon, the world\u2019s biggest eye-care company, in the first step of a deal that could become a full acquisition."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis Buys Alcon Stake From Nestl\u00e9"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""NOVARTIS"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Alcon Incorporated"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Nestle SA"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2008-04-08T04:00:00+0000"", ""document_type"": ""article"", ""news_desk"": ""ContinuousNews"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Jolly"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Jolly"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e3f093a4-b0c8-5766-8862-c1d36c9b19f6"", ""word_count"": 673, ""uri"": ""nyt://article/e3f093a4-b0c8-5766-8862-c1d36c9b19f6""}]"
2008-06-04,"{""abstract"": ""Novartis has bought U.S.-based Protez Pharmaceuticals in a deal worth up to $400 million, Reuters reported. The deal would give Novartis rights to an antibiotic which could be used to fight superbugs such as MRSA, the Swiss drugmaker said."", ""web_url"": ""https://dealbook.nytimes.com/2008/06/04/novartis-nabs-protez-for-400-million/"", ""snippet"": """", ""lead_paragraph"": ""Novartis has bought U.S.-based Protez Pharmaceuticals in a deal worth up to $400 million, Reuters reported. The deal would give Novartis rights to an antibiotic which could be used to fight superbugs such as MRSA, the Swiss drugmaker said."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis Nabs Protez for $400 Million"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2008-06-04T10:55:33+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4cf31323-6803-5acb-a6d0-2366a6afe075"", ""word_count"": 72, ""uri"": ""nyt://article/4cf31323-6803-5acb-a6d0-2366a6afe075""}"
2008-07-10,"{""abstract"": ""Novartis has taken a majority stake in Speedel Holding and offered to buy the rest in a deal valuing the company at 1.01 billion Swiss francs ($980 million), Bloomberg News reported. "", ""web_url"": ""https://dealbook.nytimes.com/2008/07/10/novartis-pays-980-million-for-speedel-majority-could-buy-remaining-shares/"", ""snippet"": """", ""lead_paragraph"": ""Novartis has taken a majority stake in Speedel Holding and offered to buy the rest in a deal valuing the company at 1.01 billion Swiss francs ($980 million), Bloomberg News reported. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis Pays $980 Million for Speedel Stake"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2008-07-10T10:33:54+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/25fe9b7a-6b3e-50d2-a220-2e369de2246a"", ""word_count"": 88, ""uri"": ""nyt://article/25fe9b7a-6b3e-50d2-a220-2e369de2246a""}"
2008-09-16,"{""abstract"": ""Amgen\u2019s experimental bone drug reduced the risk of spinal fractures in women with osteoporosis by 68 percent in a pivotal clinical trial."", ""web_url"": ""https://www.nytimes.com/2008/09/17/business/17drug.html"", ""snippet"": ""Amgen\u2019s experimental bone drug reduced the risk of spinal fractures in women with osteoporosis by 68 percent in a pivotal clinical trial."", ""lead_paragraph"": ""Amgen\u2019s experimental bone drug reduced the risk of spinal fractures in women with osteoporosis by 68 percent in a pivotal clinical trial, a robust result that raises hopes that the drug can help restore the luster of the embattled biotechnology company. "", ""print_section"": ""C"", ""print_page"": ""12"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Good Results for Bone Drug Buoy Amgen"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Good Results for Bone Drug Buoy Amgen"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Tests and Testing"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis A.G"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Credit Suisse Group"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding Ltd"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Procter & Gamble Co"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""S.A.nofi-Aventis S.A"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Osteoporosis"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 11, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ANEMIA"", ""rank"": 12, ""major"": ""N""}], ""pub_date"": ""2008-09-16T15:05:16+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c0826873-d7ea-5f37-8453-d7017d70db6f"", ""word_count"": 970, ""uri"": ""nyt://article/c0826873-d7ea-5f37-8453-d7017d70db6f""}"
2009-02-12,"{""abstract"": ""Novartis has obtained the rights to an anticlotting drug that could eventually compete with Plavix, the world\u2019s second-best-selling medicine."", ""web_url"": ""https://www.nytimes.com/2009/02/12/health/12portola.html"", ""snippet"": ""Novartis has obtained the rights to an anticlotting drug that could eventually compete with Plavix, the world\u2019s second-best-selling medicine."", ""lead_paragraph"": ""Novartis has obtained the worldwide rights to an anticlotting drug that could eventually compete with Plavix, the world\u2019s second-best-selling medicine behind the cholesterol pill Lipitor. "", ""print_section"": ""B"", ""print_page"": ""7"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis Buys Rights to a Drug to Thin Blood"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Novartis Buys Rights To a Drug To Thin Blood"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Plavix (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis A.G"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2009-02-12T05:22:02+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/fdd4d428-7688-5d34-a518-2b36981d4801"", ""word_count"": 347, ""uri"": ""nyt://article/fdd4d428-7688-5d34-a518-2b36981d4801""}"
2009-05-20,"{""abstract"": ""Novartis is buying the injectable generic cancer drugs business of Austria\u2019s EBEWE Pharma and may pursue other similar deals."", ""web_url"": ""https://dealbook.nytimes.com/2009/05/20/novartis-pays-12-billion-for-cancer-drug-unit/"", ""snippet"": ""Novartis is buying the injectable generic cancer drugs business of Austria\u2019s EBEWE Pharma and may pursue other similar deals."", ""lead_paragraph"": ""Novartis is buying the injectable generic cancer drug business of Austria\u2019s Ebewe Pharma and may pursue other similar deals as it fleshes out a planned diversification away from brand-name treatments, Reuters reported."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis Pays $1.2 Billion for Cancer Drug Unit"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-05-20T11:18:37+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/37ac1efd-88a1-5c57-aece-ec53ebc90b5b"", ""word_count"": 501, ""uri"": ""nyt://article/37ac1efd-88a1-5c57-aece-ec53ebc90b5b""}"
2009-06-17,"{""abstract"": ""The allegations relate to the takeover of NeuTec by the drug maker Novartis in 2006."", ""web_url"": ""https://www.nytimes.com/2009/06/17/business/global/17insider.html"", ""snippet"": ""The allegations relate to the takeover of NeuTec by the drug maker Novartis in 2006."", ""lead_paragraph"": ""Two lawyers who worked at the London offices of American law firms were charged with insider trading on Tuesday by a British regulator."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Three Accused of Insider Trading in Britain"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Three Accused of Insider Trading in Britain"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Insider Trading"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis A.G"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2009-06-17T01:55:54+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Global Business"", ""byline"": {""original"": ""By Bloomberg News"", ""person"": [{""firstname"": ""Bloomberg"", ""middlename"": null, ""lastname"": ""News"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/b8926297-7dc6-522f-9943-343bdeba76ca"", ""word_count"": 291, ""uri"": ""nyt://article/b8926297-7dc6-522f-9943-343bdeba76ca""}"
2009-06-29,"{""abstract"": ""Novartis is in talks to buy parts of its Irish peer Elan, including its multiple sclerosis products and its Alzheimer\u2019s disease drug pipeline, The Sunday Times reported."", ""web_url"": ""https://dealbook.nytimes.com/2009/06/29/novartis-in-talks-for-parts-of-elan-report-says/"", ""snippet"": ""Novartis is in talks to buy parts of its Irish peer Elan, including its multiple sclerosis products and its Alzheimer\u2019s disease drug pipeline, The Sunday Times reported."", ""lead_paragraph"": ""Swiss drugmaker Novartis is in talks to buy parts of Irish peer Elan, including its flagship multiple sclerosis products and its Alzheimer\u2019s disease pipeline, The Sunday Times reported."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis in Talks for Parts of Elan, Report Says"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-06-29T10:24:17+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4bfea8aa-2aba-58a8-8b8e-5639f3011ac9"", ""word_count"": 189, ""uri"": ""nyt://article/4bfea8aa-2aba-58a8-8b8e-5639f3011ac9""}"
2009-11-04,"{""abstract"": ""Novartis, the Swiss drug giant, said Wednesday it has agreed to cough up $125 million for an 85 percent stake in Chinese vaccine maker Zhejiang Tianyuan Bio-Pharmaceutical."", ""web_url"": ""https://dealbook.nytimes.com/2009/11/04/novartis-pays-125-million-for-tianyuan-stake/"", ""snippet"": ""Novartis, the Swiss drug giant, said Wednesday it has agreed to cough up $125 million for an 85 percent stake in Chinese vaccine maker Zhejiang Tianyuan Bio-Pharmaceutical."", ""lead_paragraph"": ""Novartis, the Swiss drug giant, said Wednesday it had agreed to pay $125 million for an 85 percent stake in the Chinese vaccine maker Zhejiang Tianyuan Bio-Pharmaceutical."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis Pays $125 Million for Tianyuan Stake"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2009-11-04T09:34:29+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/d7e65a83-3a92-50f8-88de-254588656cca"", ""word_count"": 88, ""uri"": ""nyt://article/d7e65a83-3a92-50f8-88de-254588656cca""}"
2009-12-24,"{""abstract"": ""Novartis, the Swiss pharmaceuticals maker, said Wednesday that it would buy the biopharmaceutical company Corthera for $120 million, giving it the right to develop a new drug against heart failure."", ""web_url"": ""https://dealbook.nytimes.com/2009/12/24/novartis-to-buy-us-firm-corthera-for-120-million/"", ""snippet"": ""Novartis, the Swiss pharmaceuticals maker, said Wednesday that it would buy the biopharmaceutical company Corthera for $120 million, giving it the right to develop a new drug against heart failure."", ""lead_paragraph"": ""Swiss pharmaceuticals maker Novartis said Wednesday it will buy U.S. biopharmaceutical company Corthera for $120 million, giving it the right to develop a new drug against heart failure."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis to Pay $120 Million for Corthera\u2019s Biotech"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2009-12-24T09:15:19+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/e905a189-0edd-5ddd-a048-946b04f07f6d"", ""word_count"": 179, ""uri"": ""nyt://article/e905a189-0edd-5ddd-a048-946b04f07f6d""}"
2010-01-04,"{""abstract"": ""Novartis, the giant Swiss drugmaker, said Monday that it would take control of the eye-care company Alcon by buying Nestl\u00e9\u2019s majority stake for $28.1 billion, raising its own stake to 77 percent, and said it would like to acquire the rest."", ""web_url"": ""https://dealbook.nytimes.com/2010/01/04/novartis-buys-majority-of-alcon-from-nestle/"", ""snippet"": ""Novartis, the giant Swiss drugmaker, said Monday that it would take control of the eye-care company Alcon by buying Nestl\u00e9\u2019s majority stake for $28.1 billion, raising its own stake to 77 percent, and said it would like to acquire the rest."", ""lead_paragraph"": ""Novartis, the giant Swiss drugmaker, said Monday that it would take control of the eye-care company Alcon by buying Nestl\u00e9\u2018s majority stake for $28.1 billion, raising its own stake to 77 percent, and said it would like to acquire the rest."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis to Buy Majority of Alcon From Nestl\u00e9"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Eyes and Eyesight"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Alcon Incorporated"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Nestle SA"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Fort Worth (Tex)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Switzerland"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2010-01-04T10:16:17+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chris V. Nicholson"", ""person"": [{""firstname"": ""Chris"", ""middlename"": ""V."", ""lastname"": ""Nicholson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/9916970d-802b-587e-a90e-cd3e143fcf6c"", ""word_count"": 687, ""uri"": ""nyt://article/9916970d-802b-587e-a90e-cd3e143fcf6c""}"
2010-01-05,"[{""abstract"": ""By buying Alcon shares from Nestl\u00e9, Novartis would raise its stake to 77 percent, and it says it wants to buy the remaining 23 percent."", ""web_url"": ""https://www.nytimes.com/2010/01/05/business/global/05iht-drug.html"", ""snippet"": ""By buying Alcon shares from Nestl\u00e9, Novartis would raise its stake to 77 percent, and it says it wants to buy the remaining 23 percent."", ""lead_paragraph"": ""Novartis, the large Swiss drug maker, said Monday that it would take control of the eye care company Alcon by buying a majority stake from Nestl\u00e9 for $28.1 billion. The move would raise its stake in Alcon to 77 percent, and Novartis said it was interested in acquiring the rest of the shares."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/01/05/business/05drug_CA0/thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/01/05/business/05drug_CA0/thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Novartis to Pay $28 Billion for a Majority Stake in Alcon"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Novartis to Pay $28 Billion for a Majority Stake in Alcon and Wants to Buy the Rest"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Alcon Incorporated"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Eyes and Eyesight"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2010-01-05T01:54:34+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Global Business"", ""byline"": {""original"": ""By Chris V. Nicholson"", ""person"": [{""firstname"": ""Chris"", ""middlename"": ""V."", ""lastname"": ""Nicholson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9844d5f3-ac80-5ce8-9bf5-27a727066390"", ""word_count"": 718, ""uri"": ""nyt://article/9844d5f3-ac80-5ce8-9bf5-27a727066390""}, {""abstract"": ""An independent committee of directors of Alcon is disappointed with a takeover bid from Novartis, saying the Swiss drug maker is trying to circumvent protections for minority shareholders."", ""web_url"": ""https://dealbook.nytimes.com/2010/01/05/alcon-directors-criticize-novartis-tactics/"", ""snippet"": ""An independent committee of directors of Alcon is disappointed with a takeover bid from Novartis, saying the Swiss drug maker is trying to circumvent protections for minority shareholders."", ""lead_paragraph"": ""An independent committee of directors of Alcon is disappointed with a takeover bid from Novartis, saying Novartis, the Swiss drug maker, is trying to circumvent protections for minority shareholders."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Alcon Directors Criticize Novartis Tactics"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Alcon Incorporated"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 4, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Switzerland"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2010-01-05T10:52:18+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/43a4966c-ca10-5890-8df5-74322804b5c9"", ""word_count"": 334, ""uri"": ""nyt://article/43a4966c-ca10-5890-8df5-74322804b5c9""}]"
2010-01-06,"{""abstract"": ""Thanks to Alcon\u2019s unique incorporation and stock listing, a mishmash of U.S. and Swiss laws applies to its proposed takeover by Novartis and the remedies available to the eye-care company\u2019s independent directors, according to the Deal Professor."", ""web_url"": ""https://dealbook.nytimes.com/2010/01/06/the-alcon-independent-directors-dilemma/"", ""snippet"": ""Thanks to Alcon\u2019s unique incorporation and stock listing, a mishmash of U.S. and Swiss laws applies to its proposed takeover by Novartis and the remedies available to the eye-care company\u2019s independent directors, according to the Deal Professor."", ""lead_paragraph"": ""Novartis\u2018s bid to acquire Alcon is an odd duck of a deal. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""The Alcon Independent Directors\u2019 Dilemma"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Regulation and Deregulation of Industry"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Alcon Incorporated"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Nestle SA"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sullivan & Cromwell"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Switzerland"", ""rank"": 8, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2010-01-06T17:08:29+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/7059eefd-440a-50a0-8fc3-4f3113a697c5"", ""word_count"": 1192, ""uri"": ""nyt://article/7059eefd-440a-50a0-8fc3-4f3113a697c5""}"
2010-01-20,"{""abstract"": ""The independent directors of Alcon, the eyecare products maker, said on Wednesday that they are challenging Novartis\u2019s bid to acquire full control of their company, calling its offer \u201cgrossly inadequate.\u201d"", ""web_url"": ""https://dealbook.nytimes.com/2010/01/20/alcon-directors-challenge-novartiss-takeover-bid/"", ""snippet"": ""The independent directors of Alcon, the eyecare products maker, said on Wednesday that they are challenging Novartis\u2019s bid to acquire full control of their company, calling its offer \u201cgrossly inadequate.\u201d"", ""lead_paragraph"": ""The independent directors of Alcon, the eye-care products maker, said on Wednesday that they are challenging Novartis\u2018s bid to acquire full control of the company, calling its offer \u201cgrossly inadequate.\u201d"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Alcon Directors Challenge Novartis\u2019s Takeover Bid"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Alcon Incorporated"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Nestle SA"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sullivan & Cromwell"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Switzerland"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Texas"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2010-01-20T12:48:28+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/ad84e681-94f2-5228-bb75-7d9bcb74b439"", ""word_count"": 206, ""uri"": ""nyt://article/ad84e681-94f2-5228-bb75-7d9bcb74b439""}"
2010-01-26,"{""abstract"": ""Novartis\u2019s bid to buy out minority shareholders in Alcon does not fairly value their holdings, one of the largest investors in the eyecare group said."", ""web_url"": ""https://dealbook.nytimes.com/2010/01/26/alcon-shareholders-push-novartis-on-bid/"", ""snippet"": ""Novartis\u2019s bid to buy out minority shareholders in Alcon does not fairly value their holdings, one of the largest investors in the eyecare group said."", ""lead_paragraph"": ""Novartis\u2018s bid to buy out minority shareholders in the eyecare company Alcon does not fairly value their holdings, one of the largest investors in Alcon said."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Alcon Shareholders Push Novartis on Bid"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Alcon Incorporated"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2010-01-26T10:23:06+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/b9cae280-2317-586c-b602-f42751022793"", ""word_count"": 101, ""uri"": ""nyt://article/b9cae280-2317-586c-b602-f42751022793""}"
2010-01-27,"{""abstract"": ""AllianceBernstein isn\u2019t usually known for making big public statements. But when it comes to Novartis\u2019s proposed takeover of the shares in Alcon it doesn\u2019t already own, the gloves are apparently off. (Read the letter on DealBook.)"", ""web_url"": ""https://dealbook.nytimes.com/2010/01/26/alliancebernstein-takes-aim-at-novartis-over-alcon-deal/"", ""snippet"": ""AllianceBernstein isn\u2019t usually known for making big public statements. But when it comes to Novartis\u2019s proposed takeover of the shares in Alcon it doesn\u2019t already own, the gloves are apparently off. (Read the letter on DealBook.)"", ""lead_paragraph"": ""AllianceBernstein, the big money manager, isn\u2019t usually known for making major public statements. But when it comes to Novartis\u2018s proposed takeover of the shares in Alcon it doesn\u2019t already own, the gloves are apparently off."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""AllianceBernstein Takes Aim at Novartis Over Alcon"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Letters"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Alcon Incorporated"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AllianceBernstein Holding LP"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Nestle SA"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2010-01-27T02:45:50+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/d9fd5672-2b7b-57ca-9678-4c25b6ac6c65"", ""word_count"": 253, ""uri"": ""nyt://article/d9fd5672-2b7b-57ca-9678-4c25b6ac6c65""}"
2010-02-01,"{""abstract"": ""The year started off exceptionally slow for mergers and acquisitions in the United States. There was only $34.2 billion worth of announced deals in January, according to Standard & Poor\u2019s Capital IQ, making it the slowest first month of the year since 2003."", ""web_url"": ""https://dealbook.nytimes.com/2010/02/01/big-chill-hit-the-deal-market-in-january/"", ""snippet"": ""The year started off exceptionally slow for mergers and acquisitions in the United States. There was only $34.2 billion worth of announced deals in January, according to Standard & Poor\u2019s Capital IQ, making it the slowest first month of the year s..."", ""lead_paragraph"": ""The year started off exceptionally slowly for mergers and acquisitions in the United States. There was only $34.2 billion worth of announced deals in January, according to Standard & Poor\u2019s Capital IQ, making it the slowest first month of the year since 2003."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Big Chill Hit the Deal Market in January"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Alcon Incorporated"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Williams Cos Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Wyeth"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2010-02-01T23:48:51+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Cyrus Sanati"", ""person"": [{""firstname"": ""Cyrus"", ""middlename"": null, ""lastname"": ""Sanati"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/8529e448-6ac9-5e60-b863-eafe7687bc94"", ""word_count"": 240, ""uri"": ""nyt://article/8529e448-6ac9-5e60-b863-eafe7687bc94""}"
2010-02-12,"{""abstract"": ""Eye care products maker Alcon, which is being acquired by Swiss drugmaker Novartis, reported higher fourth-quarter profit on Thursday, helped by double-digit sales increases in the U.S. and emerging markets."", ""web_url"": ""https://dealbook.nytimes.com/2010/02/12/alcon-profit-rises-as-novartis-takeover-looms/"", ""snippet"": ""Eye care products maker Alcon, which is being acquired by Swiss drugmaker Novartis, reported higher fourth-quarter profit on Thursday, helped by double-digit sales increases in the U.S. and emerging markets."", ""lead_paragraph"": ""Alcon, the eye-care products maker being acquired by Swiss drug maker Novartis, reported higher fourth-quarter profit on Thursday, helped by double-digit sales increases in the United States. and emerging markets, Reuters reported."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Alcon Profit Rises as Novartis Takeover Looms"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Alcon Incorporated"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 3, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Switzerland"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2010-02-12T08:23:39+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/97c082be-d433-5eb3-a3e0-f61d1e0d7389"", ""word_count"": 167, ""uri"": ""nyt://article/97c082be-d433-5eb3-a3e0-f61d1e0d7389""}"
2010-02-16,"{""abstract"": ""Drug makers are pursuing a consumer base in markets like Asia and Latin America, where many pay out of pocket for medicines but often cannot afford expensive brand-name drugs."", ""web_url"": ""https://www.nytimes.com/2010/02/16/business/16generic.html"", ""snippet"": ""Drug makers are pursuing a consumer base in markets like Asia and Latin America, where many pay out of pocket for medicines but often cannot afford expensive brand-name drugs."", ""lead_paragraph"": ""Some prestigious brand-name pharmaceutical companies that once looked askance at the high-volume, low-cost business of generic drugs are now becoming major purveyors of generic medicines."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/02/16/business/16generic_1/16generic_1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/02/16/business/16generic_1/16generic_1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Drug Firms Apply Brand to Generics"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Drug Firms Apply Brand To Generics"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medley Pharmaceuticals"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Trademarks and Trade Names"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sanofi-Aventis SA"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic and Brand Name Products"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2010-02-16T02:58:15+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/b34aa206-d31c-5002-a9bd-64589049a273"", ""word_count"": 1220, ""uri"": ""nyt://article/b34aa206-d31c-5002-a9bd-64589049a273""}"
2010-04-06,"{""abstract"": ""A complaint is seeking more than $200 million in damages from a company that has received accolades from Working Mother magazine."", ""web_url"": ""https://www.nytimes.com/2010/04/07/business/07gender.html"", ""snippet"": ""A complaint is seeking more than $200 million in damages from a company that has received accolades from Working Mother magazine."", ""lead_paragraph"": ""A class-action lawsuit alleging that Novartis Pharmaceuticals practiced sex discrimination against female employees is set to go to trial on Wednesday in federal court in New York. "", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/04/07/business/07gender_CA0/07gender_CA0-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/04/07/business/07gender_CA0/07gender_CA0-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Novartis Bias Suit to Begin"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Novartis Bias Suit To Begin"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Hiring and Promotion"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Discrimination"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Women and Girls"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2010-04-06T22:41:06+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/36225029-49dc-58f3-938e-8bda5c753769"", ""word_count"": 946, ""uri"": ""nyt://article/36225029-49dc-58f3-938e-8bda5c753769""}"
2010-04-19,"{""abstract"": ""Novartis, the Swiss drugmaker, bought the privately held American company Oriel Therapeutics to boost its generics portfolio, targeting the multibillion market for drugs against respiratory diseases, Reuters reported."", ""web_url"": ""https://dealbook.nytimes.com/2010/04/19/novartis-buys-generics-maker-oriel/"", ""snippet"": ""Novartis, the Swiss drugmaker, bought the privately held American company Oriel Therapeutics to boost its generics portfolio, targeting the multibillion market for drugs against respiratory diseases, Reuters reported."", ""lead_paragraph"": ""Novartis, the Swiss drugmaker, bought privately held American company Oriel Therapeutics to boost its generics portfolio, targeting the multibillion market for drugs against respiratory diseases, Reuters reported."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis Buys Generics Maker Oriel"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 1, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Switzerland"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2010-04-19T09:07:08+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/c688d585-f891-5c8a-a034-2b5f005e9037"", ""word_count"": 93, ""uri"": ""nyt://article/c688d585-f891-5c8a-a034-2b5f005e9037""}"
2010-05-17,"{""abstract"": ""A federal jury sides with former sales representatives who said the pharmaceutical company discriminated against them in pay and promotions."", ""web_url"": ""https://www.nytimes.com/2010/05/18/business/18novartis.html"", ""snippet"": ""A federal jury sides with former sales representatives who said the pharmaceutical company discriminated against them in pay and promotions."", ""lead_paragraph"": ""A federal jury in New York reached a verdict on Monday requiring Novartis Pharmaceuticals to pay $3.36 million to 12 former female sales representatives for discrimination in pay and promotions. "", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Women Win a Bias Suit Against Novartis"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Women Win A Bias Suit Against Novartis"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Discrimination"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Women and Girls"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Decisions and Verdicts"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2010-05-17T20:12:51+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/100dc034-ff0e-529f-95a3-7f53ddae54d1"", ""word_count"": 645, ""uri"": ""nyt://article/100dc034-ff0e-529f-95a3-7f53ddae54d1""}"
2010-06-03,"{""abstract"": ""Bill George, a Harvard business professor, looks at the conflicts within the biotechnology industry between short-term and long-term gains in light of Carl C. Icahn\u2019s attempt to win board seats at Genzyme."", ""web_url"": ""https://dealbook.nytimes.com/2010/06/03/another-view-can-biotech-survive-icahn/"", ""snippet"": ""Bill George, a Harvard business professor, looks at the conflicts within the biotechnology industry between short-term and long-term gains in light of Carl C. Icahn\u2019s attempt to win board seats at Genzyme."", ""lead_paragraph"": ""Bill George, a Harvard business professor, looks at the conflicts within the biotechnology industry between short-term and long-term gains."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Another View: Can Biotech Survive Icahn?"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Biotechnology"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Science and Technology"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""George, Bill"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Icahn, Carl C"", ""rank"": 5, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Mulligan, Richard"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Stewart, Martha"", ""rank"": 7, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Whitworth, Ralph V"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMYLIN PHARMACEUTICALS INCORPORATED"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Genzyme Corp"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Goldman Sachs Group"", ""rank"": 13, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Harvard Business School"", ""rank"": 14, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Harvard University"", ""rank"": 15, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ImClone Systems Inc"", ""rank"": 16, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""MedImmune Inc"", ""rank"": 17, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 18, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""National Institutes of Health"", ""rank"": 19, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 20, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding AG"", ""rank"": 21, ""major"": ""N""}], ""pub_date"": ""2010-06-03T13:15:18+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/107ebd6e-489e-506f-97d5-3da1482cb1a2"", ""word_count"": 901, ""uri"": ""nyt://article/107ebd6e-489e-506f-97d5-3da1482cb1a2""}"
2010-06-30,"{""abstract"": ""Alcon on Wednesday announced that it would hold a meeting on Aug. 16 for shareholders to vote on the appointment of five directors nominated by Novartis, which owns 25 percent of the Swiss eyecare drug maker."", ""web_url"": ""https://dealbook.nytimes.com/2010/06/30/date-is-set-for-vote-on-alcon-board-candidates/"", ""snippet"": ""Alcon on Wednesday announced that it would hold a meeting on Aug. 16 for shareholders to vote on the appointment of five directors nominated by Novartis, which owns 25 percent of the Swiss eyecare drug maker."", ""lead_paragraph"": ""Alcon on Wednesday announced that it would hold a meeting on Aug. 16 for shareholders to vote on the appointment of five directors nominated by Novartis, which owns 25 percent of the Swiss eyecare-drug maker."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Date Is Set for Vote on Alcon Board Candidates"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Conflicts of Interest"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Elections"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Alcon Incorporated"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Nestle SA"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Switzerland"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2010-06-30T22:02:44+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/4f8d7cdc-5984-5f32-8ca8-676105b76753"", ""word_count"": 235, ""uri"": ""nyt://article/4f8d7cdc-5984-5f32-8ca8-676105b76753""}"
2010-07-23,"{""abstract"": ""A group of investors seem quite cheered by Euthymics Bioscience\u2019s prospects, ponying up $24 million in a first round of funding for the developer of next-generation antidepressants."", ""web_url"": ""https://dealbook.nytimes.com/2010/07/23/antidepressant-maker-taps-24-million/"", ""snippet"": ""A group of investors seem quite cheered by Euthymics Bioscience\u2019s prospects, ponying up $24 million in a first round of funding for the developer of next-generation antidepressants."", ""lead_paragraph"": ""A group of investors seem quite cheered by Euthymics Bioscience\u2018s prospects, ponying up $24 million in a first round of financing for the developer of next-generation antidepressants."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Antidepressant Maker Taps $24 Million"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""State of Wisconsin Investment Board"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2010-07-23T11:37:44+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/4c6c5174-aa9e-52f2-bd6d-269b9abd818d"", ""word_count"": 74, ""uri"": ""nyt://article/4c6c5174-aa9e-52f2-bd6d-269b9abd818d""}"
2010-07-28,"{""abstract"": ""The Swiss drug giant will give away up to 250,000 bottles of a liquid medicine to woo parents frustrated by the recall of liquid children\u2019s Tylenol. "", ""web_url"": ""https://www.nytimes.com/2010/07/29/business/29drug.html"", ""snippet"": ""The Swiss drug giant will give away up to 250,000 bottles of a liquid medicine to woo parents frustrated by the recall of liquid children\u2019s Tylenol. "", ""lead_paragraph"": ""The Swiss drug giant Novartis plans to give away up to 250,000 bottles of its new liquid children\u2019s medicine, Triaminic Fever Reducer Pain Reliever, in an effort to woo parents frustrated by a nationwide recall and shortage of a competing product \u0097 liquid children\u2019s Tylenol."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/07/29/business/Drug/Drug-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2010/07/29/business/Drug/Drug-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""A Novartis Giveaway of Medicine"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""A Tylenol Alternative, Free From Novartis"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Recalls and Bans of Products"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tylenol (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2010-07-28T19:44:46+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Natasha Singer"", ""person"": [{""firstname"": ""Natasha"", ""middlename"": null, ""lastname"": ""Singer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/928a9e62-3562-54d6-8a33-e0534f0824f6"", ""word_count"": 626, ""uri"": ""nyt://article/928a9e62-3562-54d6-8a33-e0534f0824f6""}"
2010-08-02,"{""abstract"": ""Two major proxy advisory firms contend that an agreement by Novartis to take over majority control is unfair to Alcon\u2019s minority shareholders."", ""web_url"": ""https://dealbook.nytimes.com/2010/08/02/proxy-advisers-urge-vote-against-slate-for-alcon/"", ""snippet"": ""Two major proxy advisory firms contend that an agreement by Novartis to take over majority control is unfair to Alcon\u2019s minority shareholders."", ""lead_paragraph"": ""Two major proxy advisory firms have recommended that shareholders vote against Novartis\u2018s nominees to the board of Alcon, contending that an agreement by Novartis to take over majority control is unfair to Alcon\u2019s minority shareholders."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Proxy Advisers Urge Vote Against Slate for Alcon"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Alcon Incorporated"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Nestle SA"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""RiskMetrics"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2010-08-02T16:09:55+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Cyrus Sanati"", ""person"": [{""firstname"": ""Cyrus"", ""middlename"": null, ""lastname"": ""Sanati"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/f4f2b2c0-f1b6-5c3f-8bac-2f1604a03d66"", ""word_count"": 528, ""uri"": ""nyt://article/f4f2b2c0-f1b6-5c3f-8bac-2f1604a03d66""}"
2010-08-26,"{""abstract"": ""Novartis and Nestl\u00e9 said Thursday that they had wrapped up a $28.3 billion all-cash deal that gives Novartis, the Swiss drug giant, a controlling stake in the eye-care company Alcon, the last step in a deal initiated in 2008."", ""web_url"": ""https://dealbook.nytimes.com/2010/08/26/novartis-and-nestle-close-28-3-billion-alcon-deal/"", ""snippet"": ""Novartis and Nestl\u00e9 said Thursday that they had wrapped up a $28.3 billion all-cash deal that gives Novartis, the Swiss drug giant, a controlling stake in the eye-care company Alcon, the last step in a deal initiated in 2008."", ""lead_paragraph"": ""Novartis and Nestl\u00e9 said Thursday that they had wrapped up a $28.3 billion all-cash deal that gives Novartis, the Swiss drug giant, a controlling stake in the eye-care company Alcon, one of the last steps in a deal initiated in 2008."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis and Nestl\u00e9 Close $28.3 Billion Alcon Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Alcon Incorporated"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2010-08-26T12:20:32+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Dealbook"", ""person"": [{""firstname"": ""Dealbook"", ""middlename"": null, ""lastname"": """", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/140aa193-4993-5962-a9d4-09d48f432615"", ""word_count"": 133, ""uri"": ""nyt://article/140aa193-4993-5962-a9d4-09d48f432615""}"
2010-10-01,"{""abstract"": ""Federal prosecutors accused Novartis of paying illegal kickbacks to health care professionals through speaker programs, advisory boards, entertainment, travel and meals."", ""web_url"": ""https://www.nytimes.com/2010/10/01/health/policy/01novartis.html"", ""snippet"": ""Federal prosecutors accused Novartis of paying illegal kickbacks to health care professionals through speaker programs, advisory boards, entertainment, travel and meals."", ""lead_paragraph"": "" The Swiss drug giant Novartis is paying $422.5 million to settle criminal and civil investigations into the marketing of the antiseizure medicine Trileptal and five other drugs, federal officials said on Thursday."", ""print_section"": ""B"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2010/10/01/business/Novartis/Novartis-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Novartis Settles Off-Label Marketing Case Over 6 Drugs for $422.5 Million"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Novartis Settles Off-Label Marketing Case Over 6 Drugs for $422.5 Million"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Bribery and Kickbacks"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Labeling and Labels"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2010-10-01T01:39:17+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""subsection_name"": ""Money & Policy"", ""byline"": {""original"": ""By Duff Wilson"", ""person"": [{""firstname"": ""Duff"", ""middlename"": null, ""lastname"": ""Wilson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4130fbe8-4ee0-554a-a93c-f1ac3c8f6fa2"", ""word_count"": 798, ""uri"": ""nyt://article/4130fbe8-4ee0-554a-a93c-f1ac3c8f6fa2""}"
2010-10-26,"{""abstract"": ""The Deal Professor examines the state of play in Novartis\u2018s effort to squeeze out minority shareholders of Alcon now that it controls the eye care company."", ""web_url"": ""https://dealbook.nytimes.com/2010/10/26/the-endgame-for-alcon-and-novartis/"", ""snippet"": ""The Deal Professor examines the state of play in Novartis\u2018s effort to squeeze out minority shareholders of Alcon now that it controls the eye care company."", ""lead_paragraph"": ""10:54 a.m. | Updated It is very likely that we are heading into the endgame in Novartis\u2019s attempt to acquire the remaining 23 percent of the eye care company Alcon that Novartis, the big Swiss drug maker, does not already own. The tea leaves support such a conclusion."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""The Endgame for Alcon and Novartis"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Alcon Incorporated"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2010-10-26T19:47:35+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/f3b66062-fddf-55e2-afc1-f8940f7d9e56"", ""word_count"": 857, ""uri"": ""nyt://article/f3b66062-fddf-55e2-afc1-f8940f7d9e56""}"
2010-12-15,"{""abstract"": ""Novartis says it has reached an agreement with Alcon, the eye-care company, to buy the 23 percent of Alcon it does not already own."", ""web_url"": ""https://dealbook.nytimes.com/2010/12/15/novartis-wraps-up-alcon-deal-for-12-9-billion/"", ""snippet"": ""Novartis says it has reached an agreement with Alcon, the eye-care company, to buy the 23 percent of Alcon it does not already own."", ""lead_paragraph"": ""Novartis, the giant Swiss drug maker, said on Wednesday that it had reached an agreement with Alcon, the eye-care company, wrapping up a yearlong effort to buy the 23 percent of Alcon it does not already own. Novartis will use its stock to pay the equivalent of $168 for each Alcon share, valuing the transaction at $12.9 billion."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis Seals Alcon Deal for $12.9 Billion"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Alcon Incorporated"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2010-12-15T08:37:55+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chris V. Nicholson"", ""person"": [{""firstname"": ""Chris"", ""middlename"": ""V."", ""lastname"": ""Nicholson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/ac5e8752-d188-51d4-9503-2b8262976a70"", ""word_count"": 419, ""uri"": ""nyt://article/ac5e8752-d188-51d4-9503-2b8262976a70""}"
2010-12-16,"{""abstract"": ""Novartis\u2019s acquisition of Alcon and Carl C. Icahn\u2019s bid for Dynegy each provide their own distinct lessons for deal makers."", ""web_url"": ""https://dealbook.nytimes.com/2010/12/16/alcon-and-dynegy-deals-reach-a-climax/"", ""snippet"": ""Novartis\u2019s acquisition of Alcon and Carl C. Icahn\u2019s bid for Dynegy each provide their own distinct lessons for deal makers."", ""lead_paragraph"": ""They are not in time for year-end banker bonuses, but on Wednesday we approached closure on two of the more notable deals of 2010: Novartis\u2019s acquisition of Alcon and Dynegy\u2019s attempt to sell itself. They each provide their own distinct lessons for deal makers. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Alcon and Dynegy Deals Reach a Climax"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Icahn, Carl C"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Alcon Incorporated"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Dynegy Inc."", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2010-12-16T11:30:15+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/36f50f5a-44aa-5def-8750-d3422fede24e"", ""word_count"": 1423, ""uri"": ""nyt://article/36f50f5a-44aa-5def-8750-d3422fede24e""}"
2011-01-24,"{""abstract"": ""Novartis says it has agreed to buy Genoptix, an American oncology laboratory, for $470 million in cash."", ""web_url"": ""https://dealbook.nytimes.com/2011/01/24/novartis-buys-u-s-cancer-lab-for-470-million/"", ""snippet"": ""Novartis says it has agreed to buy Genoptix, an American oncology laboratory, for $470 million in cash."", ""lead_paragraph"": ""7:45 a.m. | Updated Novartis, the Swiss pharmaceutical giant, said on Monday that it had agreed to buy Genoptix, an American oncology laboratory, for $470 million in cash."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis Buys U.S. Cancer Lab for $470 Million"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""ALCON INC"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2011-01-24T09:47:47+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chris V. Nicholson"", ""person"": [{""firstname"": ""Chris"", ""middlename"": ""V."", ""lastname"": ""Nicholson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/a68f6a34-8046-5c3f-ab20-117ba11f05e1"", ""word_count"": 200, ""uri"": ""nyt://article/a68f6a34-8046-5c3f-ab20-117ba11f05e1""}"
2011-03-25,"{""abstract"": ""But predictions that Roche is now vulnerable to a takeover from Novartis, which holds a third of Roche\u2019s voting shares, may be premature."", ""web_url"": ""https://dealbook.nytimes.com/2011/03/25/roches-bloc-of-heirs-lose-majority-vote-after-one-bolts/"", ""snippet"": ""But predictions that Roche is now vulnerable to a takeover from Novartis, which holds a third of Roche\u2019s voting shares, may be premature."", ""lead_paragraph"": ""A shareholder pool made of up descendants of the founder of the Roche Holding, which controls the Swiss pharmaceutical giant, has slipped below the 50 percent threshold after one member of the family broke away, a representative for the group said Thursday."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Roche\u2019s Bloc of Heirs Lose Majority Vote After One Bolts"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding AG"", ""rank"": 2, ""major"": ""N""}], ""pub_date"": ""2011-03-25T13:31:12+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chris V. Nicholson"", ""person"": [{""firstname"": ""Chris"", ""middlename"": ""V."", ""lastname"": ""Nicholson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": """", ""_id"": ""nyt://article/dbb7576c-3d2a-572e-8124-33ca6591e99a"", ""word_count"": 403, ""uri"": ""nyt://article/dbb7576c-3d2a-572e-8124-33ca6591e99a""}"
2011-10-08,"{""abstract"": ""Joseph Jimenez, C.E.O. of Novartis, says he has learned that you can\u2019t solve a problem unless you can get to its roots."", ""web_url"": ""https://www.nytimes.com/2011/10/09/business/joseph-jimenez-of-novartis-on-finding-the-core-of-a-problem.html"", ""snippet"": ""Joseph Jimenez, C.E.O. of Novartis, says he has learned that you can\u2019t solve a problem unless you can get to its roots."", ""lead_paragraph"": ""\u00a0This interview with  Joseph Jimenez, chief executive of Novartis, the pharmaceutical company, was conducted and condensed by  Adam Bryant. "", ""print_section"": ""BU"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/10/09/business/09corner-pic/09corner-pic-jumbo.jpg"", ""height"": 290, ""width"": 190, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2011/10/09/business/09corner-pic/09corner-pic-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2011/10/09/business/09corner-pic/09corner-pic-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Fix the Problem, and Not Just the Symptoms"", ""kicker"": ""Corner Office | Joseph Jimenez"", ""content_kicker"": null, ""print_headline"": ""Fix the Problem, and Not Just the Symptoms"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Hiring and Promotion"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Careers and Professions"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executives and Management"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis A.G"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2011-10-08T17:23:33+0000"", ""document_type"": ""article"", ""news_desk"": ""NAT"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Adam Bryant"", ""person"": [{""firstname"": ""Adam"", ""middlename"": null, ""lastname"": ""Bryant"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""Question"", ""_id"": ""nyt://article/cb9c54bc-a49e-5a52-8529-dd026ec3951a"", ""word_count"": 1916, ""uri"": ""nyt://article/cb9c54bc-a49e-5a52-8529-dd026ec3951a""}"
2011-12-08,"{""abstract"": ""Clinical trials of the treatments, from Novartis and Genentech, showed they could lengthen lives."", ""web_url"": ""https://www.nytimes.com/2011/12/08/health/research/two-drugs-appear-to-delay-progression-of-breast-cancer.html"", ""snippet"": ""Clinical trials of the treatments, from Novartis and Genentech, showed they could lengthen lives."", ""lead_paragraph"": ""Two drugs can delay by several months the time before advanced breast cancer worsens, potentially providing new options for women with that disease, researchers reported Wednesday. "", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Two Drugs Appear to Delay Progression of Breast Cancer"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Two Drugs Appear to Delay Progression of Breast Cancer"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Genentech Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Breast Cancer"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis A.G"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2011-12-08T03:51:18+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""subsection_name"": ""Research"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/285836a3-221a-5901-a675-451a28f3c123"", ""word_count"": 821, ""uri"": ""nyt://article/285836a3-221a-5901-a675-451a28f3c123""}"
2012-02-24,"{""abstract"": ""Budget cuts mean governments are not willing to pay as much for pills, and new laws in some countries require companies to prove drugs are effective or risk losing coverage."", ""web_url"": ""https://www.nytimes.com/2012/02/24/business/austerity-in-europe-puts-pressure-on-drug-companies.html"", ""snippet"": ""Budget cuts mean governments are not willing to pay as much for pills, and new laws in some countries require companies to prove drugs are effective or risk losing coverage."", ""lead_paragraph"": ""PARIS \u2014Profits at pharmaceutical companies have been declining or showing little growth for the last year as austerity measures across Europe lead to cuts in health care spending. Some analysts say this trend could continue until at least 2014."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/02/24/business/Pharma/Pharma-jumbo.jpg"", ""height"": 826, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/02/24/business/Pharma/Pharma-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2012/02/24/business/Pharma/Pharma-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Austerity in Europe Puts Pressure on Drug Companies"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Austerity in Europe Puts Pressure on Drug Companies"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""European Sovereign Debt Crisis (2010- )"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Europe"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2012-02-24T03:15:03+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Stephanie Novak"", ""person"": [{""firstname"": ""Stephanie"", ""middlename"": null, ""lastname"": ""Novak"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/fb7ec227-4ef5-581e-8034-48a4c665463c"", ""word_count"": 1030, ""uri"": ""nyt://article/fb7ec227-4ef5-581e-8034-48a4c665463c""}"
2012-03-06,"[{""abstract"": ""India\u2019s mass production of generic versions of drugs patented elsewhere helps poor people with treatment that would otherwise be too costly, but drug companies say the knockoffs stifle innovation."", ""web_url"": ""https://www.nytimes.com/2012/03/07/business/global/indias-supreme-court-to-hear-long-simmering-dispute-on-drug-patents.html"", ""snippet"": ""India\u2019s mass production of generic versions of drugs patented elsewhere helps poor people with treatment that would otherwise be too costly, but drug companies say the knockoffs stifle innovation."", ""lead_paragraph"": ""MUMBAI, India \u2014 While China was becoming the world\u2019s shop floor, India took its place as the world\u2019s pharmacy, and in recent decades has been the largest provider of cheap, lifesaving medicines in poor countries across the globe."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/03/07/business/global/07generics-span/07generics-span-articleLarge.jpg"", ""height"": 350, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2012/03/07/business/global/07generics-span/07generics-span-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 350}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/03/07/business/global/07generics-span/07generics-span-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/03/07/business/global/07generics-span/07generics-span-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2012/03/07/business/global/07generics-span/07generics-span-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""India\u2019s Supreme Court to Hear Dispute on Drug Patents"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Patent v. Patient"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""glocations"", ""value"": ""India"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""International Trade and World Market"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Inventions and Patents"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic Brands and Products"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2012-03-06T14:43:47+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Global Business"", ""byline"": {""original"": ""By Vikas Bajaj and Andrew Pollack"", ""person"": [{""firstname"": ""Vikas"", ""middlename"": null, ""lastname"": ""Bajaj"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/f3959b8c-0f94-505f-b291-816321eb4f47"", ""word_count"": 1469, ""uri"": ""nyt://article/f3959b8c-0f94-505f-b291-816321eb4f47""}, {""abstract"": ""A study finds that digital health records may not cut costs; a patent challenge threatens production of a cancer drug in India; and Texas teachers buy a stake in a hedge fund."", ""web_url"": ""https://www.nytimes.com/video/business/100000001409207/busines-day-live-march-6-2012.html"", ""snippet"": ""A study finds that digital health records may not cut costs; a patent challenge threatens production of a cancer drug in India; and Texas teachers buy a stake in a hedge fund."", ""lead_paragraph"": ""A study finds that digital health records may not cut costs; a patent challenge threatens production of a cancer drug in India; and Texas teachers buy a stake in a hedge fund."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/03/06/business/video-bdl-120306/video-bdl-120306-articleLarge.jpg"", ""height"": 338, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2012/03/06/business/video-bdl-120306/video-bdl-120306-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 338}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2012/03/06/business/video-bdl-120306/video-bdl-120306-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2012/03/06/business/video-bdl-120306/video-bdl-120306-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}], ""headline"": {""main"": ""Business Day Live | March 6, 2012"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Lohr, Steve"", ""rank"": 1, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""India"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hedge Funds"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 4, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Texas"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Teachers and School Employees"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Inventions and Patents"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2012-03-06T16:26:46+0000"", ""document_type"": ""multimedia"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""Mac William Bishop, Pedro Rosado, Nadia Sussman and David Frank"", ""person"": [{""firstname"": ""Mac"", ""middlename"": ""William"", ""lastname"": ""Bishop"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Pedro"", ""middlename"": null, ""lastname"": ""Rosado"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}, {""firstname"": ""Nadia"", ""middlename"": null, ""lastname"": ""Sussman"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 3}, {""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Frank"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 4}], ""organization"": null}, ""type_of_material"": ""Video"", ""_id"": ""nyt://video/976cd904-cd43-53ad-8154-45923d0f4183"", ""word_count"": 0, ""uri"": ""nyt://video/976cd904-cd43-53ad-8154-45923d0f4183""}]"
2012-05-02,"{""abstract"": ""Novartis International agreed to buy Fougera Pharmaceuticals, a maker of generic skin care medicine, in a move that would make it the biggest manufacturer in the field."", ""web_url"": ""https://dealbook.nytimes.com/2012/05/02/novartis-to-buy-fougera-pharmaceuticals-for-1-5-billion/"", ""snippet"": ""Novartis International agreed to buy Fougera Pharmaceuticals, a maker of generic skin care medicine, in a move that would make it the biggest manufacturer in the field."", ""lead_paragraph"": ""Novartis International agreed on Wednesday to buy Fougera Pharmaceuticals, a maker of generic skin care medicine, for $1.525 billion in cash. The move would make the company the biggest manufacturer in the field."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis to Buy Fougera Pharmaceuticals for $1.5 Billion"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Fougera Pharmaceuticals Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2012-05-02T21:17:53+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/925d79f6-410c-5540-82f5-c6a1f719c166"", ""word_count"": 246, ""uri"": ""nyt://article/925d79f6-410c-5540-82f5-c6a1f719c166""}"
2012-07-21,"{""abstract"": ""The drugs for breast cancer and multiple myeloma will be given to patients in advanced stages of those diseases."", ""web_url"": ""https://www.nytimes.com/2012/07/21/health/research/fda-approves-afinitor-and-kyprolis-for-breast-cancer-and-myeloma.html"", ""snippet"": ""The drugs for breast cancer and multiple myeloma will be given to patients in advanced stages of those diseases."", ""lead_paragraph"": ""New drugs for breast cancer and multiple myeloma won approval from the Food and Drug Administration on Friday, expanding options for patients in advanced stages of those diseases. "", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""F.D.A. Approves Drugs for Cancer and Myeloma"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""F.D.A. Approves Drugs for Cancer and Myeloma"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Onyx Pharmaceuticals"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Breast Cancer"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Myeloma"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2012-07-21T00:58:29+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Health"", ""subsection_name"": ""Research"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/bda52f04-12da-549c-94eb-eb86aa122715"", ""word_count"": 569, ""uri"": ""nyt://article/bda52f04-12da-549c-94eb-eb86aa122715""}"
2012-08-06,"{""abstract"": ""The alliance seeks to build on the results of an experimental treatment that trains a person\u2019s immune system to kill cancer cells."", ""web_url"": ""https://www.nytimes.com/2012/08/06/business/novartis-and-penn-unite-on-anticancer-approach.html"", ""snippet"": ""The alliance seeks to build on the results of an experimental treatment that trains a person\u2019s immune system to kill cancer cells."", ""lead_paragraph"": ""The drugmaker Novartis and the University of Pennsylvania announced a research and licensing agreement early Monday that aims to bring to market a new approach to fighting cancer that has shown promising results in early trials."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis and Penn Unite on New Anticancer Path"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Novartis and Penn Unite On New Anticancer Path"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""University of Pennsylvania"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Colleges and Universities"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2012-08-06T05:15:02+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/01263e02-7b13-58f2-9531-cd230c957f2a"", ""word_count"": 424, ""uri"": ""nyt://article/01263e02-7b13-58f2-9531-cd230c957f2a""}"
2012-12-07,"{""abstract"": ""The drug maker Mylan is suing the Food and Drug Administration in an attempt to upend its rival Ranbaxy\u2019s exclusive rights to produce a generic form of Diovan, a blood pressure drug."", ""web_url"": ""https://www.nytimes.com/2012/12/07/business/mylan-sues-fda-over-ranbaxys-rights-to-diovan.html"", ""snippet"": ""The drug maker Mylan is suing the Food and Drug Administration in an attempt to upend its rival Ranbaxy\u2019s exclusive rights to produce a generic form of Diovan, a blood pressure drug."", ""lead_paragraph"": ""The Swiss drug maker Novartis had been bracing all year for the day in late September when Diovan, its top-selling blood pressure drug, would lose patent protection and a cheaper generic version would become available."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Lawsuit Challenges Ranbaxy\u2019s Rights to Generic Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Lawsuit Challenges Ranbaxy\u2019s Rights to Generic Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Blood Pressure"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Mylan Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Ranbaxy Laboratories"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic Brands and Products"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2012-12-07T02:52:42+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/01335c03-147c-5a1f-bf14-9c2e95408b51"", ""word_count"": 566, ""uri"": ""nyt://article/01335c03-147c-5a1f-bf14-9c2e95408b51""}"
2013-01-31,"{""abstract"": ""Johnson & Johnson and Novartis were accused of colluding to delay the availability of a less expensive version of a pain medication for cancer patients."", ""web_url"": ""https://www.nytimes.com/2013/02/01/business/global/eu-says-drug-makers-paid-to-delay-generic-version.html"", ""snippet"": ""Johnson & Johnson and Novartis were accused of colluding to delay the availability of a less expensive version of a pain medication for cancer patients."", ""lead_paragraph"": ""BRUSSELS \u2014 European antitrust officials on Thursday accused the drug giants Johnson & Johnson and Novartis of colluding to delay the availability of a less expensive generic version of a powerful medication often used to ease severe pain in cancer patients."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/01/business/EUDrug/EUDrug-articleLarge.jpg"", ""height"": 768, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/02/01/business/EUDrug/EUDrug-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 768}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/01/business/EUDrug/EUDrug-jumbo.jpg"", ""height"": 1024, ""width"": 800, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/01/business/EUDrug/EUDrug-superJumbo.jpg"", ""height"": 1516, ""width"": 1184, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/01/business/EUDrug/EUDrug-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/02/01/business/EUDrug/EUDrug-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/01/business/EUDrug/EUDrug-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Europe Says Drug Makers Paid to Delay a Generic"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Drug Giant Paid to Stop A Generic, Europe Says"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Johnson & Johnson"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Kanter, James"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sandoz International GmbH"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Janssen-Cilag"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Antitrust Laws and Competition Issues"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""European Commission"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 9, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Pain-Relieving Drugs"", ""rank"": 10, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Europe"", ""rank"": 11, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 12, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Almunia, Joaquin"", ""rank"": 13, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic Brands and Products"", ""rank"": 14, ""major"": ""N""}], ""pub_date"": ""2013-01-31T20:06:21+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Global Business"", ""byline"": {""original"": ""By James Kanter and Katie Thomas"", ""person"": [{""firstname"": ""James"", ""middlename"": null, ""lastname"": ""Kanter"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e68d2492-ae1a-5c4c-8076-3e0006838919"", ""word_count"": 1138, ""uri"": ""nyt://article/e68d2492-ae1a-5c4c-8076-3e0006838919""}"
2013-02-18,"{""abstract"": ""The drug maker plans to pay Daniel Vasella, its departing chairman, $78 million to prevent him from sharing knowledge with competitors."", ""web_url"": ""https://www.nytimes.com/2013/02/19/business/global/for-daniel-vasella-of-novartis-78-million-to-keep-secrets.html"", ""snippet"": ""The drug maker plans to pay Daniel Vasella, its departing chairman, $78 million to prevent him from sharing knowledge with competitors."", ""lead_paragraph"": ""LONDON \u2014 A plan by Novartis, one of Switzerland\u2019s biggest drug makers, to pay its departing chairman $78 million to keep him from sharing his knowledge with competitors has added fuel to an already heated debate about executive pay."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/19/business/19novartis-web/19novartis-web-articleLarge.jpg"", ""height"": 314, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/02/19/business/19novartis-web/19novartis-web-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 314}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/19/business/19novartis-web/19novartis-web-jumbo.jpg"", ""height"": 536, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/19/business/19novartis-web/19novartis-web-superJumbo.jpg"", ""height"": 1072, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/19/business/19novartis-web/19novartis-web-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/02/19/business/19novartis-web/19novartis-web-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/19/business/19novartis-web/19novartis-web-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": "" Critics of Executive Pay Put Pressure on Novartis "", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Critics of Executive Pay Put Pressure on Novartis"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Werdigier, Julia"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executive Compensation"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Wages and Salaries"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Vasella, Daniel L"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2013-02-18T19:49:46+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Global Business"", ""byline"": {""original"": ""By Julia Werdigier"", ""person"": [{""firstname"": ""Julia"", ""middlename"": null, ""lastname"": ""Werdigier"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/6685428a-1770-5036-9544-3d1ecd137f54"", ""word_count"": 509, ""uri"": ""nyt://article/6685428a-1770-5036-9544-3d1ecd137f54""}"
2013-02-19,"{""abstract"": ""The Swiss drug company faced criticism from shareholders and lawmakers for agreeing to pay Daniel Vasella $78 million over six years."", ""web_url"": ""https://www.nytimes.com/2013/02/20/business/global/novartis-scraps-non-compete-payment-to-departing-chairman.html"", ""snippet"": ""The Swiss drug company faced criticism from shareholders and lawmakers for agreeing to pay Daniel Vasella $78 million over six years."", ""lead_paragraph"": ""LONDON \u2014 Novartis, one of Switzerland\u2019s biggest drug makers, said Tuesday it scrapped a planned $78 million payment to its departing chairman because of pressure from shareholders and lawmakers."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/19/business/19novartis-web/19novartis-web-articleLarge.jpg"", ""height"": 314, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/02/19/business/19novartis-web/19novartis-web-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 314}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/19/business/19novartis-web/19novartis-web-jumbo.jpg"", ""height"": 536, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/19/business/19novartis-web/19novartis-web-superJumbo.jpg"", ""height"": 1072, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/19/business/19novartis-web/19novartis-web-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/02/19/business/19novartis-web/19novartis-web-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/02/19/business/19novartis-web/19novartis-web-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Novartis Scraps Non-Compete Payment to Departing Chairman"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Big Payout By Novartis Is Canceled"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Werdigier, Julia"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executive Compensation"", ""rank"": 3, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Switzerland"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Vasella, Daniel L"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2013-02-19T11:31:30+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Global Business"", ""byline"": {""original"": ""By Julia Werdigier"", ""person"": [{""firstname"": ""Julia"", ""middlename"": null, ""lastname"": ""Werdigier"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/071b77ed-d4d6-5a45-8c43-b2223073606d"", ""word_count"": 604, ""uri"": ""nyt://article/071b77ed-d4d6-5a45-8c43-b2223073606d""}"
2013-03-01,"{""abstract"": ""The Swiss are set to vote on a proposal that would give shareholders a binding say on compensation for executives and board members."", ""web_url"": ""https://www.nytimes.com/2013/03/02/business/global/showdown-on-executive-compensation-in-switzerland.html"", ""snippet"": ""The Swiss are set to vote on a proposal that would give shareholders a binding say on compensation for executives and board members."", ""lead_paragraph"": ""GENEVA \u2014 For Thomas Minder, a decade-long crusade against \u201cfat cats\u201d is coming to a head."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/03/02/business/subFatcat/subFatcat-articleLarge.jpg"", ""height"": 370, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/03/02/business/subFatcat/subFatcat-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 370}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/03/02/business/subFatcat/subFatcat-jumbo.jpg"", ""height"": 631, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/03/02/business/subFatcat/subFatcat-superJumbo.jpg"", ""height"": 1263, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Showdown on Executive Compensation in Switzerland"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Showdown on Executive Pay in Switzerland Goes to a Vote"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Executive Compensation"", ""rank"": 2, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Switzerland"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Regulation and Deregulation of Industry"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2013-03-01T13:16:33+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Global Business"", ""byline"": {""original"": ""By Raphael Minder"", ""person"": [{""firstname"": ""Raphael"", ""middlename"": null, ""lastname"": ""Minder"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/f036a7ab-2c2a-5957-904b-a19d3861b930"", ""word_count"": 1201, ""uri"": ""nyt://article/f036a7ab-2c2a-5957-904b-a19d3861b930""}"
2013-04-01,"[{""abstract"": ""Production of cheap copycat drugs for H.I.V. and cancer used by people in developing countries in Africa and Asia was ensured on Monday in a ruling by India\u2019s Supreme Court."", ""web_url"": ""https://www.nytimes.com/2013/04/02/business/global/top-court-in-india-rejects-novartis-drug-patent.html"", ""snippet"": ""Production of cheap copycat drugs for H.I.V. and cancer used by people in developing countries in Africa and Asia was ensured on Monday in a ruling by India\u2019s Supreme Court."", ""lead_paragraph"": ""NEW DELHI \u2014 People in developing countries worldwide will continue to have access to low-cost copycat versions of drugs for diseases like H.I.V. and cancer, at least for a while. "", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/02/business/Patent/Patent-articleLarge.jpg"", ""height"": 388, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/04/02/business/Patent/Patent-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 388}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/02/business/Patent/Patent-jumbo.jpg"", ""height"": 663, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/02/business/Patent/Patent-superJumbo.jpg"", ""height"": 1325, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/02/business/Patent/Patent-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/04/02/business/Patent/Patent-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/02/business/Patent/Patent-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Low-Cost Drugs in Poor Nations Get a Lift in Indian Court"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Low-Cost Drugs In Poor Nations Get Lift in Court"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""glocations"", ""value"": ""India"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Inventions and Patents"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic Brands and Products"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Supreme Court of India"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Decisions and Verdicts"", ""rank"": 9, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Third World and Developing Countries"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2013-04-01T06:47:15+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Global Business"", ""byline"": {""original"": ""By Gardiner Harris and Katie Thomas"", ""person"": [{""firstname"": ""Gardiner"", ""middlename"": null, ""lastname"": ""Harris"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/3e409532-5394-5fac-9946-7982c7667c61"", ""word_count"": 1285, ""uri"": ""nyt://article/3e409532-5394-5fac-9946-7982c7667c61""}, {""abstract"": ""The Times\u2019s Katie Thomas explains why a ruling in India favoring generic drugs has rippling effects around the world."", ""web_url"": ""https://www.nytimes.com/video/business/global/100000002148616/drug-debate.html"", ""snippet"": ""The Times\u2019s Katie Thomas explains why a ruling in India favoring generic drugs has rippling effects around the world."", ""lead_paragraph"": ""The Times\u2019s Katie Thomas explains why a ruling in India favoring generic drugs has rippling effects around the world."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/01/business/video-tc-130401-genericdrugs/video-tc-130401-genericdrugs-articleLarge.jpg"", ""height"": 338, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/04/01/business/video-tc-130401-genericdrugs/video-tc-130401-genericdrugs-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 338}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/01/business/video-tc-130401-genericdrugs/video-tc-130401-genericdrugs-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/04/01/business/video-tc-130401-genericdrugs/video-tc-130401-genericdrugs-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/01/business/video-tc-130401-genericdrugs/video-tc-130401-genericdrugs-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Big Court Ruling Favors Generic Drugs"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Inventions and Patents"", ""rank"": 1, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""India"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2013-04-01T15:52:12+0000"", ""document_type"": ""multimedia"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Global Business"", ""byline"": {""original"": ""Ben Werschkul, Channon Hodge, Erica Berenstein and Alyssa Kim"", ""person"": [{""firstname"": ""Ben"", ""middlename"": null, ""lastname"": ""Werschkul"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Channon"", ""middlename"": null, ""lastname"": ""Hodge"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}, {""firstname"": ""Erica"", ""middlename"": null, ""lastname"": ""Berenstein"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 3}, {""firstname"": ""Alyssa"", ""middlename"": null, ""lastname"": ""Kim"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 4}], ""organization"": null}, ""type_of_material"": ""Video"", ""_id"": ""nyt://video/7c55f36b-1ccc-5cc4-a87e-fac603a83131"", ""word_count"": 0, ""uri"": ""nyt://video/7c55f36b-1ccc-5cc4-a87e-fac603a83131""}]"
2013-04-04,"{""abstract"": ""A campaign for the drug maker Novartis uses the slogan \u201cHey MS, Take This!\u201d and shows patients sticking out their tongues with capsules on them in defiance of the disease."", ""web_url"": ""https://www.nytimes.com/2013/04/04/business/media/an-ms-drug-takes-a-feisty-approach-aimed-at-younger-patients.html"", ""snippet"": ""A campaign for the drug maker Novartis uses the slogan \u201cHey MS, Take This!\u201d and shows patients sticking out their tongues with capsules on them in defiance of the disease."", ""lead_paragraph"": ""THE Swiss drug maker Novartis is taking a sassy new tack to win converts to its oral multiple sclerosis treatment, Gilenya. Its \u201cHey MS, Take This!\u201d campaign shows patients sticking out their tongues with Gilenya capsules on them to show their willingness to fight back against the neurological condition."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/04/business/Adco/Adco-articleLarge.jpg"", ""height"": 337, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/04/04/business/Adco/Adco-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 337}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/04/business/Adco/Adco-jumbo.jpg"", ""height"": 575, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/04/business/Adco/Adco-superJumbo.jpg"", ""height"": 1077, ""width"": 1919, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/04/business/Adco/Adco-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/04/04/business/Adco/Adco-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/04/business/Adco/Adco-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""An MS Drug Takes a Feisty Approach Aimed at Younger Patients"", ""kicker"": ""Advertising"", ""content_kicker"": null, ""print_headline"": ""An MS Drug Takes a Feisty Approach Aimed at Younger Patients"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Olson, Elizabeth"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Multiple Sclerosis"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2013-04-04T02:06:17+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Media"", ""byline"": {""original"": ""By Elizabeth Olson"", ""person"": [{""firstname"": ""Elizabeth"", ""middlename"": null, ""lastname"": ""Olson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/169e0dd5-1a1b-5254-a23f-221c1eab562b"", ""word_count"": 902, ""uri"": ""nyt://article/169e0dd5-1a1b-5254-a23f-221c1eab562b""}"
2013-04-15,"{""abstract"": ""Big pharmaceutical companies are using a safety law to prevent generic manufacturers from developing low-cost copies of their drugs."", ""web_url"": ""https://www.nytimes.com/2013/04/16/business/drug-makers-use-safety-rule-to-block-generics.html"", ""snippet"": ""Big pharmaceutical companies are using a safety law to prevent generic manufacturers from developing low-cost copies of their drugs."", ""lead_paragraph"": ""For decades, pharmaceutical companies have deployed an array of tactics aimed at preventing low-cost copies of their drugs from entering the marketplace."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/16/business/16generic-web2/16generic-web2-jumbo.jpg"", ""height"": 255, ""width"": 395, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/16/business/16generic-web2/16generic-web2-superJumbo.jpg"", ""height"": 255, ""width"": 395, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/16/business/16generic-web2/16generic-web2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/04/16/business/16generic-web2/16generic-web2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/16/business/16generic-web2/16generic-web2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Drug Makers Use Safety Rule to Block Generics"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Game Plan Against Generics"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic Brands and Products"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Federal Trade Commission"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Celgene Corporation"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""APOTEX INC"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Lundbeck Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Gilead Sciences Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Lannett Company Inc"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Acorda Therapeutics Inc"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Actelion Pharmaceuticals Ltd"", ""rank"": 13, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Accord Healthcare"", ""rank"": 14, ""major"": ""N""}], ""pub_date"": ""2013-04-15T22:38:33+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/0efd682f-cbea-5529-8679-c541a365f976"", ""word_count"": 1200, ""uri"": ""nyt://article/0efd682f-cbea-5529-8679-c541a365f976""}"
2013-04-24,"{""abstract"": ""A lawsuit accuses the drug company of giving pharmacies discounts in exchange for promoting a drug."", ""web_url"": ""https://www.nytimes.com/2013/04/24/business/us-accuses-novartis-of-providing-kickbacks.html"", ""snippet"": ""A lawsuit accuses the drug company of giving pharmacies discounts in exchange for promoting a drug."", ""lead_paragraph"": ""Federal prosecutors in New York filed a lawsuit on Tuesday accusing Novartis of providing illegal kickbacks to pharmacies, in the form of discounts and rebates, to promote use of one of the company\u2019s drugs. "", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""U.S. Accuses Novartis of Providing Kickbacks"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""U.S. Accuses Novartis Of Providing Kickbacks"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation (Civil)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugstores"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Kidneys"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Bribery and Kickbacks"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2013-04-24T01:40:54+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8a9c699c-4410-5366-bbc7-f760acc3c967"", ""word_count"": 583, ""uri"": ""nyt://article/8a9c699c-4410-5366-bbc7-f760acc3c967""}"
2013-04-25,"{""abstract"": ""More than 100 influential cancer specialists argued in a journal that some drug prices are unsustainable and perhaps even immoral."", ""web_url"": ""https://www.nytimes.com/2013/04/26/business/cancer-physicians-attack-high-drug-costs.html"", ""snippet"": ""More than 100 influential cancer specialists argued in a journal that some drug prices are unsustainable and perhaps even immoral."", ""lead_paragraph"": ""With the cost of some lifesaving cancer drugs exceeding $100,000 a year, more than 100 influential cancer specialists from around the world have taken the unusual step of banding together in hopes of persuading some leading pharmaceutical companies to bring prices down."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/26/business/26drug/26drug-articleLarge.jpg"", ""height"": 416, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/04/26/business/26drug/26drug-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 416}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/26/business/26drug/26drug-jumbo.jpg"", ""height"": 710, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/26/business/26drug/26drug-superJumbo.jpg"", ""height"": 1421, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/26/business/26drug/26drug-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/04/26/business/26drug/26drug-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/04/26/business/26drug/26drug-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Doctors Denounce Cancer Drug Prices of $100,000 a Year"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Cancer Specialists Attack High Drug Costs"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Prices (Fares, Fees and Rates)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Health Insurance and Managed Care"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Leukemia"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Blood (Journal)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2013-04-25T14:04:03+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ef1800ab-acdd-591b-9158-78baf2a8a45e"", ""word_count"": 1366, ""uri"": ""nyt://article/ef1800ab-acdd-591b-9158-78baf2a8a45e""}"
2013-06-14,"{""abstract"": ""The pharmaceutical company, which sells a treatment for immune-related ailments at $28,000 a vial, bought a much cheaper alternative of the drug."", ""web_url"": ""https://www.nytimes.com/2013/06/15/business/questcor-pays-135-million-for-rights-to-competitors-drug.html"", ""snippet"": ""The pharmaceutical company, which sells a treatment for immune-related ailments at $28,000 a vial, bought a much cheaper alternative of the drug."", ""lead_paragraph"": ""A pharmaceutical company that has reaped huge profits by selling a 60-year-old drug for $28,000 a vial has eliminated the most obvious threat of competition from a much cheaper drug by acquiring the rights to it."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/06/15/business/Quest/Quest-jumbo.jpg"", ""height"": 681, ""width"": 454, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/06/15/business/Quest/Quest-superJumbo.jpg"", ""height"": 681, ""width"": 454, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/06/15/business/Quest/Quest-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/06/15/business/Quest/Quest-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/06/15/business/Quest/Quest-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Questcor Pays $135 Million to Acquire Rights to a Competitor\u2019s Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Questcor Pays $135 Million to Acquire Rights to a Competitor\u2019s Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Acthar (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Questcor Pharmaceuticals Incorporated"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Immune System"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2013-06-14T21:51:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4e05a1d8-43b1-56e3-99e6-14d4c59a5d4b"", ""word_count"": 836, ""uri"": ""nyt://article/4e05a1d8-43b1-56e3-99e6-14d4c59a5d4b""}"
2013-08-12,"{""abstract"": ""The Alcon unit of Novartis and AARP join forces to educate baby boomers about the procedure."", ""web_url"": ""https://www.nytimes.com/2013/08/12/business/media/ads-seek-to-clear-up-qualms-about-cataract-surgery.html"", ""snippet"": ""The Alcon unit of Novartis and AARP join forces to educate baby boomers about the procedure."", ""lead_paragraph"": ""Though it ultimately proved unsuccessful, the advertising campaign that introduced the phrase \u201cThis is not your father\u2019s Oldsmobile\u201d has had considerable influence on popular culture, with the phrase entering the vernacular as shorthand for something, usually in the commercial realm, that has been updated for a new generation of consumers."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/08/12/business/media/12adnews-1-span/12adnews-1-span-articleLarge.jpg"", ""height"": 392, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2013/08/12/business/media/12adnews-1-span/12adnews-1-span-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 392}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/08/12/business/media/12adnews-1-span/12adnews-1-span-jumbo.jpg"", ""height"": 669, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/08/12/business/media/12adnews-1-span/12adnews-1-span-superJumbo.jpg"", ""height"": 1339, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/08/12/business/media/12adnews-1-span/12adnews-1-span-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2013/08/12/business/media/12adnews-1-span/12adnews-1-span-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2013/08/12/business/media/12adnews-1-span/12adnews-1-span-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Ads Seek to Clear Up Qualms About Cataract Surgery"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Cataracts"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Publicis Groupe SA"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""DDB Worldwide"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AARP"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Starcom Mediavest Group"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2013-08-12T16:52:23+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Media"", ""byline"": {""original"": ""By Stuart Elliott"", ""person"": [{""firstname"": ""Stuart"", ""middlename"": null, ""lastname"": ""Elliott"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c5a65fa0-10df-5265-979b-2da1d8575d2d"", ""word_count"": 1161, ""uri"": ""nyt://article/c5a65fa0-10df-5265-979b-2da1d8575d2d""}"
2013-11-11,"{""abstract"": ""The sale by the Swiss pharmaceutical company comes as part of an effort to focus on its larger business units."", ""web_url"": ""https://dealbook.nytimes.com/2013/11/11/novartis-to-sell-diagnostics-unit-to-grifols-for-1-7-billion/"", ""snippet"": ""The sale by the Swiss pharmaceutical company comes as part of an effort to focus on its larger business units."", ""lead_paragraph"": ""Novartis, the Swiss pharmaceuticals group, is selling its diagnostics business to Spanish health care company Grifols S.A. for $1.7 billion in an all-cash deal."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis to Sell Diagnostics Unit to Grifols for $1.7 Billion"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Grifols SA"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2013-11-11T06:40:50+0000"", ""document_type"": ""article"", ""news_desk"": """", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/79d23c4d-d54e-508d-bb39-8c8a27473b16"", ""word_count"": 345, ""uri"": ""nyt://article/79d23c4d-d54e-508d-bb39-8c8a27473b16""}"
2014-01-09,"{""abstract"": ""The government has called for a criminal investigation into ads that allegedly used flawed research to promote expanded use of a top-selling drug."", ""web_url"": ""https://www.nytimes.com/2014/01/10/business/international/novartis-faces-possible-criminal-inquiry-in-japan.html"", ""snippet"": ""The government has called for a criminal investigation into ads that allegedly used flawed research to promote expanded use of a top-selling drug."", ""lead_paragraph"": ""TOKYO \u2014 The pharmaceutical company Novartis said Thursday that it would cooperate with the authorities after Japan\u2019s Health Ministry called for a criminal investigation into ads that allegedly claimed additional benefits of its best-selling medicine Diovan based on flawed research."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis Faces Possible Criminal Inquiry in Japan"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Crime and Criminals"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-01-09T08:39:26+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""International Business"", ""byline"": {""original"": ""By Hiroko Tabuchi"", ""person"": [{""firstname"": ""Hiroko"", ""middlename"": null, ""lastname"": ""Tabuchi"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/0ca8c287-1aa9-57ae-a13b-1e5dece0fa1c"", ""word_count"": 410, ""uri"": ""nyt://article/0ca8c287-1aa9-57ae-a13b-1e5dece0fa1c""}"
2014-03-05,"{""abstract"": ""The Swiss drug companies were ordered to pay a total of $250 million for trying to keep doctors from prescribing a relatively inexpensive eye treatment."", ""web_url"": ""https://www.nytimes.com/2014/03/06/business/international/italy-fines-novartis-and-roche-in-collusion-case.html"", ""snippet"": ""The Swiss drug companies were ordered to pay a total of $250 million for trying to keep doctors from prescribing a relatively inexpensive eye treatment."", ""lead_paragraph"": ""PARIS \u2014 Italian antitrust authorities said on Wednesday that they had fined two Swiss pharmaceutical companies, Novartis and Roche Holdings, a total of $250 million for colluding to keep doctors from prescribing a relatively inexpensive eye treatment in favor of a more expensive drug."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Italy Fines Novartis and Roche in Collusion Case"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""2 Pharmaceutical Makers Fined for Undermining a Rival\u2019s Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Jolly, David"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Avastin (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding A G"", ""rank"": 5, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Italy"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Antitrust Laws and Competition Issues"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-03-05T12:33:23+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""International Business"", ""byline"": {""original"": ""By David Jolly"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Jolly"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/68f8e46b-988c-5e1d-bff6-e07e2d2fa17f"", ""word_count"": 818, ""uri"": ""nyt://article/68f8e46b-988c-5e1d-bff6-e07e2d2fa17f""}"
2014-04-07,"{""abstract"": ""Questcor Pharmaceuticals has been criticized for steadily raising the price of its most valuable product, but that aggressive pricing strategy appears to have paid off for the drug maker."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/07/mallinckrodt-to-buy-californias-questcor-for-5-6-billion/"", ""snippet"": ""Questcor Pharmaceuticals has been criticized for steadily raising the price of its most valuable product, but that aggressive pricing strategy appears to have paid off for the drug maker."", ""lead_paragraph"": ""Updated, 8:22 p.m. | Questcor Pharmaceuticals has been criticized for steadily raising the price of its most valuable product \u2014 a 60-year-old immune system drug \u2014 to more than $28,000 a vial from $40 in just a decade. Critics have said the price increases were excessive, and short-sellers have predicted the company\u2019s business and stock price would collapse. "", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/08/business/Drug/Drug-jumbo.jpg"", ""height"": 589, ""width"": 589, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/08/business/Drug/Drug-superJumbo.jpg"", ""height"": 589, ""width"": 589, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/08/business/Drug/Drug-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/04/08/business/Drug/Drug-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/08/business/Drug/Drug-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Mallinckrodt Pharmaceuticals to Buy Questcor for $5.6 Billion"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Acthar (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Autoimmune Diseases"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Boards of Directors"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 7, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Bailey, Don M"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Barclays PLC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Cadence Pharmaceuticals Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Centerview Partners"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Chronic Disease Fund"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Justice Department"", ""rank"": 13, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Latham & Watkins LLP"", ""rank"": 14, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Mallinckrodt Pharmaceuticals"", ""rank"": 15, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 16, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Questcor Pharmaceuticals Incorporated"", ""rank"": 17, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Securities and Exchange Commission"", ""rank"": 18, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""WACHTELL LIPTON ROSEN & KATZ"", ""rank"": 19, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""ANAHEIM (CALIF)"", ""rank"": 20, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""California"", ""rank"": 21, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Dublin (Ireland)"", ""rank"": 22, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""San Diego (Calif)"", ""rank"": 23, ""major"": ""N""}], ""pub_date"": ""2014-04-07T12:33:02+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack and Chad Bray"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c5ff02a5-e175-5e35-8e6a-5e7194cdbf00"", ""word_count"": 719, ""uri"": ""nyt://article/c5ff02a5-e175-5e35-8e6a-5e7194cdbf00""}"
2014-04-22,"[{""abstract"": ""Novartis will buy GlaxoSmithKline\u2019s cancer drug business for as much as $16 billion, and Glaxo will buy Novartis\u2019s vaccine business for as much as $7.1 billion."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/22/novartis-announces-major-restructuring/"", ""snippet"": ""Novartis will buy GlaxoSmithKline\u2019s cancer drug business for as much as $16 billion, and Glaxo will buy Novartis\u2019s vaccine business for as much as $7.1 billion."", ""lead_paragraph"": ""Updated, 8:18 p.m. | The Swiss pharmaceutical giant Novartis and its British rival GlaxoSmithKline announced on Tuesday that they would swap more than $20 billion in assets as they seek to sharpen the focus of their businesses."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis and Glaxo Agree to Trade $20 Billion in Assets"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Novartis and Glaxo Agree to Trade $20 Billion in Assets"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Botox (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vaccination and Immunization"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Ackman, William A"", ""rank"": 5, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Jimenez, Joseph"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Eli Lilly and Company"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pershing Square Capital Management"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 12, ""major"": ""N""}], ""pub_date"": ""2014-04-22T06:18:35+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray and David Jolly"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Jolly"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1516d147-6e27-5310-beaa-bc4982cb144f"", ""word_count"": 734, ""uri"": ""nyt://article/1516d147-6e27-5310-beaa-bc4982cb144f""}, {""abstract"": ""William A. Ackman and Valeant are bidding for Allergan, the maker of Botox. | Novartis announced a major overhaul. | AstraZeneca says no to a deal with Pfizer. | Barclays is set to exit its commodities business."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/22/morning-agenda-ackmans-botox-ambitions/"", ""snippet"": ""William A. Ackman and Valeant are bidding for Allergan, the maker of Botox. | Novartis announced a major overhaul. | AstraZeneca says no to a deal with Pfizer. | Barclays is set to exit its commodities business."", ""lead_paragraph"": ""William A. Ackman, one of the brashest men on Wall Street, has come up with perhaps the boldest move yet for an activist: He has teamed up with the health care company Valeant to bid roughly $50 billion for Allergan, the maker of Botox, David Gelles, Michael J. de la Merced and Alexandra Stevenson write in DealBook. The offer by Valeant is expected to be announced Tuesday morning."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Ackman\u2019s Botox Ambitions"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-04-22T12:11:47+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4e027bef-017e-5f33-9c69-f72c49d464c2"", ""word_count"": 1946, ""uri"": ""nyt://article/4e027bef-017e-5f33-9c69-f72c49d464c2""}]"
2014-04-23,"{""abstract"": ""Pharmaceutical companies are on the prowl for deals. | The Allergan bid charts new territory for takeovers. | Preet Bharara\u2019s perfect record is in jeopardy. | Comcast looks to divest subscribers."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/23/morning-agenda-big-pharmas-deal-bonanza/"", ""snippet"": ""Pharmaceutical companies are on the prowl for deals. | The Allergan bid charts new territory for takeovers. | Preet Bharara\u2019s perfect record is in jeopardy. | Comcast looks to divest subscribers."", ""lead_paragraph"": ""The pharmaceutical industry is regaining its swagger, Michael J. de la Merced, David Gelles and Rachel Abrams write in DealBook. On Tuesday alone, pharmaceutical companies announced $74 billion worth of potential deals, including an unconventional $45.6 billion bid for Allergan, the maker of Botox, and a flurry of swaps and sales between Novartis of Switzerland and GlaxoSmithKline of Britain. More deals in the cash-rich industry are expected."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Big Pharma\u2019s Deal Bonanza"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-04-23T11:46:07+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/02a31d94-eb4e-5a60-b361-9be61b7fa04d"", ""word_count"": 1881, ""uri"": ""nyt://article/02a31d94-eb4e-5a60-b361-9be61b7fa04d""}"
2014-05-29,"{""abstract"": ""The government says the national health service suffered losses from the drug companies\u2019 efforts to restrict competition in ophthalmic drugs."", ""web_url"": ""https://www.nytimes.com/2014/05/30/business/international/italy-seeks-1-6-billion-in-damages-from-roche-and-novartis.html"", ""snippet"": ""The government says the national health service suffered losses from the drug companies\u2019 efforts to restrict competition in ophthalmic drugs."", ""lead_paragraph"": ""PARIS \u2014 The Italian government is seeking $1.6 billion in damages from two of the world\u2019s biggest drug companies \u2014 Novartis and Roche \u2014 for losses that it says the national health service incurred from the companies\u2019 efforts to restrict competition in ophthalmic drugs."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Italy Seeks $1.6 Billion in Damages From Roche and Novartis"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Novartis and Roche Face Fines in Italy"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Jolly, David"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pianigiani, Gaia"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Antitrust Laws and Competition Issues"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Italy"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-05-29T16:26:04+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""International Business"", ""byline"": {""original"": ""By David Jolly and Gaia Pianigiani"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Jolly"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Gaia"", ""middlename"": null, ""lastname"": ""Pianigiani"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/99050c46-617e-5a06-9a52-08fd3ecde0c8"", ""word_count"": 449, ""uri"": ""nyt://article/99050c46-617e-5a06-9a52-08fd3ecde0c8""}"
2014-06-02,"{""abstract"": ""The deal with the biotechnology company Adaptimmune comes a little over a month after Glaxo agreed to sell its cancer drug business to the Swiss pharmaceutical maker Novartis."", ""web_url"": ""https://dealbook.nytimes.com/2014/06/02/glaxosmithkline-in-350-million-cancer-drug-venture/"", ""snippet"": ""The deal with the biotechnology company Adaptimmune comes a little over a month after Glaxo agreed to sell its cancer drug business to the Swiss pharmaceutical maker Novartis."", ""lead_paragraph"": ""LONDON \u2013 Adaptimmune, a biotechnology company, said on Monday that it had reached a deal that could be worth more than $350 million to develop an early stage cancer drug with the pharmaceutical maker GlaxoSmithKline."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-articleLarge.jpg"", ""height"": 401, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 401}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-jumbo.jpg"", ""height"": 684, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-superJumbo.jpg"", ""height"": 1368, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""GlaxoSmithKline in $350 Million Cancer Drug Venture"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Biotechnology"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""England"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-06-02T09:04:35+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/7d47d352-eb38-5874-8cc5-ec0ad240c08a"", ""word_count"": 302, ""uri"": ""nyt://article/7d47d352-eb38-5874-8cc5-ec0ad240c08a""}"
2014-07-09,"{""abstract"": ""An experimental drug for eczema relieved severity of symptoms in 85 percent of those who took it. A drug for psoriasis cut severity of symptoms in as many as 82 percent of those who took it."", ""web_url"": ""https://www.nytimes.com/2014/07/10/business/drugs-show-promise-in-treating-eczema-and-psoriasis-in-trials.html"", ""snippet"": ""An experimental drug for eczema relieved severity of symptoms in 85 percent of those who took it. A drug for psoriasis cut severity of symptoms in as many as 82 percent of those who took it."", ""lead_paragraph"": ""New drugs that block highly specific parts of the immune system are showing remarkable promise in treating two maddening skin diseases, eczema and psoriasis, according to papers published Wednesday in a leading medical journal."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""In Small Trials, 2 Drugs Go Far in Soothing Symptoms of Eczema and Psoriasis"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""In Small Trials, 2 Drugs Go Far in Soothing Symptoms of Eczema and Psoriasis"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Enbrel (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Skin"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Psoriasis"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Eczema"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""New England Journal of Medicine"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2014-07-09T21:53:41+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ebba55b2-9e13-559a-b2bb-da8492cc2efc"", ""word_count"": 1039, ""uri"": ""nyt://article/ebba55b2-9e13-559a-b2bb-da8492cc2efc""}"
2014-07-15,"{""abstract"": ""The Alcon unit of the European drug maker will help with one of the latest moves into the health care sector by the tech industry."", ""web_url"": ""https://www.nytimes.com/2014/07/16/business/international/novartis-joins-with-google-to-develop-contact-lens-to-monitor-blood-sugar.html"", ""snippet"": ""The Alcon unit of the European drug maker will help with one of the latest moves into the health care sector by the tech industry."", ""lead_paragraph"": ""LONDON \u2014 Google announced on Tuesday a partnership with the European drug maker Novartis to develop a smart contact lens with the potential to monitor the wearer\u2019s blood sugar levels."", ""print_section"": ""B"", ""print_page"": ""9"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/international/16google-pic/16google-pic-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/07/16/business/international/16google-pic/16google-pic-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/international/16google-pic/16google-pic-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/international/16google-pic/16google-pic-superJumbo.jpg"", ""height"": 1000, ""width"": 1500, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/international/16google-pic/16google-pic-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/07/16/business/international/16google-pic/16google-pic-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/international/16google-pic/16google-pic-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Novartis Joins With Google to Develop Contact Lens That Monitors Blood Sugar"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Novartis Joins With Google to Develop Contact Lens That Monitors Blood Sugar"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Google Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Contact Lenses"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Diabetes"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Wearable Computing"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2014-07-15T13:41:38+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""International Business"", ""byline"": {""original"": ""By Mark Scott"", ""person"": [{""firstname"": ""Mark"", ""middlename"": null, ""lastname"": ""Scott"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/49563634-f745-57c8-997c-05bc0a710741"", ""word_count"": 491, ""uri"": ""nyt://article/49563634-f745-57c8-997c-05bc0a710741""}"
2014-08-30,"{""abstract"": ""The experimental drug developed by the Swiss company Novartis reduced the risk of dying from cardiovascular causes and could replace what has been the bedrock treatment for more than 20 years, researchers said."", ""web_url"": ""https://www.nytimes.com/2014/08/31/business/new-novartis-drug-shows-striking-efficacy-in-treating-heart-failure.html"", ""snippet"": ""The experimental drug developed by the Swiss company Novartis reduced the risk of dying from cardiovascular causes and could replace what has been the bedrock treatment for more than 20 years, researchers said."", ""lead_paragraph"": ""An experimental drug has shown a striking efficacy in prolonging the lives of people with heart failure and could replace what has been the bedrock treatment for more than 20 years, researchers said on Saturday."", ""print_section"": ""A"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""New Novartis Drug Effective in Treating Heart Failure"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""New Novartis Drug Effective in Treating Heart Failure"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Heart"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""New England Journal of Medicine"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-08-30T11:00:03+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/7c7ef98a-4cf9-5643-82e4-d8fe94e84db6"", ""word_count"": 948, ""uri"": ""nyt://article/7c7ef98a-4cf9-5643-82e4-d8fe94e84db6""}"
2015-01-09,"{""abstract"": ""In search of an alternative to hearing aids or implants, some report success in early trials for drugs to improve hearing or silence tinnitus."", ""web_url"": ""https://www.nytimes.com/2015/01/10/business/ear-disorders-long-neglected-attract-drug-makers-attention-.html"", ""snippet"": ""In search of an alternative to hearing aids or implants, some report success in early trials for drugs to improve hearing or silence tinnitus."", ""lead_paragraph"": ""Driving to a meeting in 2008, Jay Lichter, a venture capitalist, suddenly became so dizzy he had to pull over and call a friend to take him to the emergency room."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-articleLarge-v2.jpg"", ""height"": 411, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/01/10/business/10ear-web1/10ear-web1-articleLarge-v2.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 411}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-jumbo-v2.jpg"", ""height"": 702, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-superJumbo-v2.jpg"", ""height"": 1405, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/01/10/business/10ear-web1/10ear-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""From Vertigo to Tinnitus, Ear Ailments Are New Focus for Drugs  "", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Music to the Ears"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Ears and Hearing"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Otonomy Inc."", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Auris Medical Holding A.G."", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Start-ups"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tinnitus"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding AG"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Avalon Ventures Limited"", ""rank"": 13, ""major"": ""N""}], ""pub_date"": ""2015-01-09T20:31:58+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/77297f1a-2dbd-57a9-a2e9-8e4a55b021e0"", ""word_count"": 1501, ""uri"": ""nyt://article/77297f1a-2dbd-57a9-a2e9-8e4a55b021e0""}"
2015-06-18,"{""abstract"": ""A federal appeals court on Thursday again invalidated a patent protecting Teva Pharmaceutical\u2019s big-selling drug, Copaxone, which can cost $60,000 a year."", ""web_url"": ""https://www.nytimes.com/2015/06/19/business/ruling-may-clear-way-for-generic-version-of-multiple-sclerosis-drug.html"", ""snippet"": ""A federal appeals court on Thursday again invalidated a patent protecting Teva Pharmaceutical\u2019s big-selling drug, Copaxone, which can cost $60,000 a year."", ""lead_paragraph"": ""The first generic version of a multiple sclerosis drug went on the market Thursday, hours after a federal appeals court again invalidated a patent for the brand-name drug, Copaxone, a major moneymaker for Teva Pharmaceutical."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Teva Ruling Clears Way for Generic Version of Multiple Sclerosis Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Teva Loses Patent Case on Lucrative Multiple Sclerosis Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic Brands and Products"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Multiple Sclerosis"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Teva Pharmaceutical Industries Ltd"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sandoz International GmbH"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Momenta Pharmaceuticals Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Inventions and Patents"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2015-06-18T18:46:34+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/6d5e161b-7dfa-5ee8-a06e-1049f0f52138"", ""word_count"": 557, ""uri"": ""nyt://article/6d5e161b-7dfa-5ee8-a06e-1049f0f52138""}"
2015-06-29,"{""abstract"": ""As part of the deal, Celgene will acquire 9.1 million shares of Juno, a leader in cancer drugs that use patients\u2019 immune systems to attack tumors."", ""web_url"": ""https://www.nytimes.com/2015/06/30/business/celgene-to-pay-1-billion-for-biotech-collaboration-with-juno.html"", ""snippet"": ""As part of the deal, Celgene will acquire 9.1 million shares of Juno, a leader in cancer drugs that use patients\u2019 immune systems to attack tumors."", ""lead_paragraph"": ""Celgene, a leading biotech company, said on Monday that it would pay about $1 billion to start a collaboration with Juno Therapeutics, a leader in the hot new area of cancer drugs that harness patients\u2019 immune systems to attack tumors."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/06/30/business/30IMMUNE/30IMMUNE-articleLarge.jpg"", ""height"": 414, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/06/30/business/30IMMUNE/30IMMUNE-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 414}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/06/30/business/30IMMUNE/30IMMUNE-jumbo.jpg"", ""height"": 707, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/06/30/business/30IMMUNE/30IMMUNE-superJumbo.jpg"", ""height"": 1330, ""width"": 1927, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/06/30/business/30IMMUNE/30IMMUNE-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/06/30/business/30IMMUNE/30IMMUNE-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/06/30/business/30IMMUNE/30IMMUNE-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Celgene to Pay $1 Billion for Biotech Collaboration With Juno"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Celgene to Pay $1 Billion for Juno Collaboration"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Celgene Corporation"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Juno Therapeutics Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Biotechnology and Bioengineering"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tumors"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2015-06-29T22:10:30+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/2edf1930-1b99-5711-92c6-65d435af39b6"", ""word_count"": 708, ""uri"": ""nyt://article/2edf1930-1b99-5711-92c6-65d435af39b6""}"
2015-07-07,"{""abstract"": ""The drug, Entresto, could eventually achieve more than $5 billion in annual sales, said Novartis, which developed it."", ""web_url"": ""https://www.nytimes.com/2015/07/08/business/international/fda-approves-heart-drug-entresto-after-promising-trial-results.html"", ""snippet"": ""The drug, Entresto, could eventually achieve more than $5 billion in annual sales, said Novartis, which developed it."", ""lead_paragraph"": ""The Food and Drug Administration on Tuesday approved a new heart failure drug from Novartis that has been shown to reduce death and hospitalizations from the condition."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""F.D.A. Approves Heart Drug Entresto Said to Cut Death Risk by 20%"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""F.D.A. Approves Drug Said to Cut Death Risk in Heart Patients by 20 Percent"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Heart"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2015-07-07T22:31:27+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""International Business"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/de9940a5-33f2-5ee5-a6bd-11a492aae9b5"", ""word_count"": 715, ""uri"": ""nyt://article/de9940a5-33f2-5ee5-a6bd-11a492aae9b5""}"
2015-07-29,"{""abstract"": ""The Swiss giant is putting three drugs in development into a new entity backed by investors. With biotech markets hot, there\u2019s room for copycat deals."", ""web_url"": ""https://www.nytimes.com/2015/07/30/business/dealbook/novartis-spinoff-shows-alternative-to-big-drug-makers.html"", ""snippet"": ""The Swiss giant is putting three drugs in development into a new entity backed by investors. With biotech markets hot, there\u2019s room for copycat deals."", ""lead_paragraph"": ""Biotechnology investors can be better than big pharmaceutical companies at valuing and nurturing small drugs. Recognizing this, Novartis is spinning three drugs in development into a new entity backed by British investors. With biotech markets hot, there\u2019s room for copycat deals."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis Spinoff Shows Alternative to Big Drug Makers"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Biotechnology and Bioengineering"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Mereo BioPharma Group Ltd"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2015-07-29T20:02:16+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Neil Unmack"", ""person"": [{""firstname"": ""Neil"", ""middlename"": null, ""lastname"": ""Unmack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/311dd382-193d-56c7-b593-181cc1833a79"", ""word_count"": 338, ""uri"": ""nyt://article/311dd382-193d-56c7-b593-181cc1833a79""}"
2015-08-21,"{""abstract"": ""The experimental drug ofatumumab would bolster the Swiss pharmaceutical company\u2019s portfolio of multiple sclerosis treatments."", ""web_url"": ""https://www.nytimes.com/2015/08/22/business/dealbook/novartis-buys-glaxo-drug-for-1-billion.html"", ""snippet"": ""The experimental drug ofatumumab would bolster the Swiss pharmaceutical company\u2019s portfolio of multiple sclerosis treatments."", ""lead_paragraph"": ""Novartis bolstered its portfolio of multiple sclerosis treatments on Friday by agreeing to buy an experimental drug from GlaxoSmithKline for up to $1 billion, the company said."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis to Buy Multiple Sclerosis Drug From Glaxo"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Business Briefing; Novartis Buys Glaxo Multiple Sclerosis Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Tsang, Amie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Multiple Sclerosis"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2015-08-21T08:39:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Dealbook"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Amie Tsang and Andrew Pollack"", ""person"": [{""firstname"": ""Amie"", ""middlename"": null, ""lastname"": ""Tsang"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/5ed849e1-1704-5052-bc58-04c6f955c320"", ""word_count"": 528, ""uri"": ""nyt://article/5ed849e1-1704-5052-bc58-04c6f955c320""}"
